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ABSTRACT 
 
Fanconi anemia (FA) is a genetic chromosomal instability disorder characterized 
by progressive bone marrow failure and a strong predisposition to cancer.  The FA 
proteins work together in a cellular pathway for the repair of DNA interstrand crosslinks 
(ICLs).  Currently 22 different FA genes are implicated in this disease and contribute to 
the heterogeneity in symptoms and severity. Using gene targeting techniques, we 
successfully created a set of isogenic knockout cell lines to represents all 3 groups of 
proteins within the FA pathway to characterize protein function and identify differences 
that help explain FA disease heterogeneity.   
In Chapter 2 we investigate the FA group 2 proteins, FANCI and FANCD2 that 
that form a heterodimer called the ID complex.  We characterized the FANCI, FANCD2 
and FANCI/FANCD2 double knockout cell lines and identified non-overlapping 
functions in the replication stress response.  In fact, we found that only FANCD2 is 
required for restart of stalled replication forks and FANCI may even inhibit restart when 
FANCD2 is absent.  In addition, FANCD2 has a more vital role in homologous 
recombination, and FANCI promotes apoptosis in the absence of FANCD2 with 
replication stress.   
In Chapter 3 we investigate FANCN, an FA group 3 protein that is associated 
with more severe FA disease.  We used FANCN conditional knockout cells to determine 
that FANCN is essential for viability and genome stability.  In addition, we evaluated 
FANCN FA-associated mutations and breast cancer-associated variants of unknown 
significance (VUS) mutations.  We confirmed that the BRCA1/2 binding domains of 
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FANCN are not essential for viability and identified two VUS mutations as potentially 
pathogenic.  
In conclusion, we have demonstrated alternative functions of FA proteins in 
response to replication stress as a potential source of FA disease heterogeneity.  In 
addition, we have demonstrated that FANCN is essential for viability whereas FANCI 
and FANCD2 are not, providing insight into both the frequency of occurrence and 
severity of FA disease associated with these different genes.  Finally, we created isogenic 
cell lines that are a valuable asset for the FA and breast cancer fields for further 
investigations into protein function, characterization of patient mutations, and screening 
novel therapeutics. 
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Fanconi anemia 
Fanconi anemia (FA) was first described in 1927 by a Swiss pediatrician, Guido Fanconi, 
who reported on three brothers who all died at a young age with a severe form of anemia 
along with what has subsequently been recognized as the other characteristic symptoms 
of FA(1).  Most cases of FA are inherited as an autosomal recessive genetic disease, but 
X-linked and a rare autosomal-dominant form of inheritance have also been 
identified(2,3).  FA is estimated to occur in approximately 1 in 360,000 live births and 
can be caused by mutation of any of 22 currently recognized FA genes (denoted 
sequentially as FANCA to FANCW)(2,4).  Of these 22 genes, 6 have been discovered in 
just the past 2 years, and there are still FA patients with undetermined genetic causes(4-
11).  Therefore, it is highly likely that new FA genes still remain to be discovered. 
 
FA clinical symptoms, diagnosis and treatment 
Clinical symptoms:  Due to the genetic heterogeneity of the disease and a varied 
penetrance, there are a wide range of clinical symptoms associated with FA (12).  The 
two most common and lethal symptoms are bone marrow failure and a strong 
predisposition to cancer(13).  The hematological symptoms associated with bone marrow 
failure typically begin prior to the age of 10 and include aplastic anemia, myelodysplastic 
syndrome (MDS), or acute myeloid leukemia (AML)(13).  Aplastic anemia is when the 
body is not making enough of all three blood cell types, and is also called pancytopenia.  
The three blood cell types include white blood cells (leukocytes), red blood cells 
(erythrocytes) and platelets (thrombocytes)(14).  Low white blood cells (leukopenia) can 
increase the risk of infection, and low red blood cells (anemia) results in fatigue, 
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headaches, dizziness and exercise intolerance.  Furthermore, low platelets 
(thrombocytopenia) results in bleeding issues, such as nose bleeds, gastrointestinal (GI) 
bleeding and stroke risks(14).  Another possible hematological symptom of FA, MDS, 
occurs when blood cells are dysmorphic and typically is also associated with the 
reduction in one or more type of blood cell (cytopenia)(14).  The last hematological 
symptom of FA is a rapidly progressing form of leukemia, called AML, and FA patients 
are at a 800-fold higher risk for AML than the general population (13).  FA patients are 
also prone to solid tumors, especially squamous cell carcinomas (SCC) of the head and 
neck, esophageal and gynecological tract (15).  All cancers in FA are aggressive and 
typically difficult to treat due to the inability of FA patients to handle normal 
chemotherapy and radiation regimens.  
Other common symptoms of FA are morphological defects that are found in about 60 
to 75% of FA patients and often include anomalies of the thumb and forearm, kidney and 
urinary tract malformation, short stature and microcephaly(13,16,17).  Furthermore, it is 
common for patients to have café au lait spots and other types of abnormal skin 
pigmentation(13,17).  Indeed, patients with more severe malformation are often 
diagnosed with FA earlier and prior to marrow failure as compared to patients with mild 
to moderate aesthetic malformation who are often only diagnosed later when symptoms 
of bone marrow failure appear. 
 
Diagnosis: It has been well established that FA cells derived from any of the 22 genetic 
subtypes are highly sensitive to DNA interstrand crosslinks (ICLs).  These highly toxic 
DNA lesions result from the covalent crosslinking of the two strands of double-stranded 
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DNA, and can interfere with both replication and transcription(18).  The frequent 
occurrence and inability to repair/resolve ICLs is used in the diagnosis of FA.  Thus, a 
patient suspected of having FA can be confirmed (or eliminated) as having the disease by 
a chromosomal fragility assay in which the patient's peripheral blood lymphocytes are 
treated with a DNA cross-linking agent such as mitomycin C (MMC) or 1,2,3,4-
diepoxybutane (DEB) and then scored for the characteristic chromosomal breakage and 
radial formations that occur when authentic FA cells are exposed to these drugs(19).  
While hypersensitivity to MMC or DEB is often sufficient to diagnose a patient in the 
clinic the converse (i.e., a lack of sensitivity) is not always sufficient to rule a patient out.  
Thus, FA has a high rate of hematopoietic somatic mosaicism where a gene conversion or 
an additional mutation occurs, allowing for the functional correction of one allele and, 
consequently, a negative chromosomal breakage assay result(20-24).  A strong selective 
advantage for this type of compensating mutation has been observed in some patients 
when a gene conversion event occurs in a hematopoietic progenitor cell, and can result in 
the repopulation of blood cells and hematological improvement(23,25).  Therefore, if a 
chromosomal breakage assay using lymphocytes is negative, but FA is still suspected, 
fibroblasts from the patient would then next be tested for chromosomal breakage with an 
ICL inducing agent, where the occurrence of such rescuing mutations is much lower(26).   
Treatment: Currently, the only effective curative treatment for the BMF associated with 
FA is a hematopoietic stem cell transplant (HSCT).  Impressively, improvements in the 
management of patient symptoms and in HSCT technology have extended the life 
expectancy for FA patients and many now live into adulthood; something that occurred 
rarely even just a decade ago(5,13). 
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Fanconi anemia and the BRCA pathway in ICL repair 
Unrepaired ICLs are highly toxic to cells, especially to rapidly dividing cells and that is 
why ICL-inducing agents are such effective chemotherapeutics (27).  ICLs can be 
generated from both exogenous and endogenous sources.  Exogenous sources include 
chemotherapeutics such as MMC and DEB and these are not typical exposure risks.  
However, endogenous ICLs can occur from the consumption of dietary lipids, alcohols, 
and the nitrates used in food preservation (27).  ICLs can even be caused by the 
spontaneous hydrolysis of the glycosidic bonds in DNA abasic sites (28-30). 
All of the current 22 FA genes are believed to function together in a DNA repair 
pathway called the FA/breast cancer allele (BRCA) pathway for ICL repair(5,31).  
Within this pathway, the genes are organized into 3 groups:  1) the upstream and core 
complex proteins, 2) the central ID complex, and 3) the downstream proteins.  The 
FA/BRCA pathway is primarily only active in S-phase of the cell cycle and is activated 
by the convergence of two replication forks on the ICL lesion (Figure 1A-D) (32,33).   
 
Upstream/core complex: In response to the ICL, FANCM is first phosphorylated by the 
checkpoint kinase, ataxia telangiectasia and RAD3-related (ATR), and then subsequently 
binds to the ICL (34,35).  FANCM then recruits the FA core complex composed of eight 
FA proteins and five FA-associated proteins (FANCA, FANCB, FANCC, FANCE, 
FANCF, FANCG, FANCL, FANCM, FA core complex associated protein 100 
(FAAP100), FANCM interacting histone-fold protein 1 (MHF1), MHF2, FAAP20 and 
FAAP24).  The core complex is then responsible for the monoubiquitination of FANCI 
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and FANCD2 (hereafter the ID complex) through the FANCL E3 ubiquitin ligase 
subunit, along with FANCT/UBE2T, the E2 ubiquitin conjugating enzyme (Figure 1A) 
(11,36,37).  Mutations in any of the upstream/core complex FA proteins results in no 
monoubiquitinated FANCD2 (FANCD2-Ub).  This phenotype (i.e., the presence or 
absence of FANCD2-Ub) can be used to determine if an undetermined mutated gene in a 
patient is an upstream or downstream FA/BRCA pathway gene. 
 
ID complex: FANCI and FANCD2 form a heterodimer termed the ID complex(38,39).  
Both FANCD2 and FANCI are phosphorylated by ATR in response to ICLs, and only if 
both proteins are present will either become monoubiquitinated by the core complex: 
FANCI is monubiquitinated at lysine 523, and FANCD2 at lysine 561 (40).  The 
monoubiquitinated ID complex then localizes to chromatin and facilitates the unhooking 
of the ICL through the recruitment of downstream nucleases (Figure 1A-B) (41,42). 
 
Downstream proteins: Once on chromatin, FANCD2-Ub recruits FANCP/SLX4, which 
is a nuclease scaffold protein(43-45).  FANCP, in turn, then recruits several 
endonucleases including the FANCQ/XPF/ERCC4:excision repair cross complementing 
gene 1 (ERCC1) heterodimer (41,46,47).  The FANCQ:ERCC1 heterodimer is involved 
in unhooking of the ICL by nucleolytic incision and creating a DNA double strand break 
(DSB) on one DNA duplex of the replication fork and a DNA lesion on the other (Figure 
1B).  Translesion DNA synthesis is used to replicate over the lesion on the latter DNA 
duplex.  Specifically, FANCV/MAD2L2/REV7 is a component of DNA polymerase 
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ζ (polζ), a translesion polymerase that can insert nucleotides directly across from DNA 
lesions including DNA adducts, abasic sites and DNA crosslinks (Figure 1C) (2,48,49).  
Finally, FANCS/BRCA1, FANCD1/BRCA2, FANCJ/BRIP1, FANCN/PALB2, 
FANCO/RAD51C, FANCR/RAD51, FANCU/XRCC2 and FANCW/RFWD3 are all 
involved in homologous recombination (HR) to restore the chromosome on the second 
DNA duplex containing the DSB (Figure 1D) (50,51).  Curiously, deactivation of the FA 
pathway by USP1, a deubiquitinating enzyme that removes the monoubiquitin from 
FANCD2 is important for ICL resistance as well.  In fact, the knockout of USP1 in DT40 
chicken cells and in the mouse leads to increased levels of monoubiquitinated FANCD2, 
but also to increased ICL sensitivity (52,53). 
A defining factor of the downstream proteins is that the monoubiquitination of FANCD2 
is not dependent on their function, consequently if a FA patient has a downstream protein 
mutation, FANCD2-Ub will not be affected.  Therefore, whether or not FANCD2 can 
become monoubiquitinated in a new FA patient can be used to narrow down the search 
for the causative mutations and FA subtype determination.    
 
FA proteins involved in alternative functions 
While all FA patient cells are sensitive to ICL-inducing agents, not all the clinical 
symptoms and phenotypes of FA patients can be explained by cellular defects in ICL 
repair.  In agreement with this, many FA proteins have been implicated in multiple 
alternative functions outside of the canonical FA/BRCA ICL repair pathway (54-56).  
These alternative functions include the involvement of FA proteins in the replication 
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stress response, R-loop resolution, and cell cycle progression and each of these may also 
help to maintain the genomic integrity of the cell. 
 
Replication stress response:  Replication stress can lead to genomic instability and be a 
driving factor in tumorigenesis (57,58).  Replication stress can occur endogenously 
through the attempt to replicate through highly repetitive chromosomal regions including 
trinucleotide repeats (TNRs), telomeres, long interspersed nuclear elements (LINEs), 
short interspersed nuclear elements (SINEs), DNA transposons and ALU repeat elements 
(59-61).  These repetitive elements can transiently form complex DNA structures such as 
hairpins, triplexes and quadraplexes that create obstacles for replication resulting in the 
stalling of replication forks (59,62).  Additionally, common fragile sites (CFS) that are 
late replicating, AT-rich regions are often sites of DNA breakage when the cell is under 
replication stress (63,64).  These difficult to replicate regions are sources of genomic 
instability to a cell that is under replicative stress. 
Experimentally, replication stress can be induced by the addition of hydroxyurea 
(HU) or aphidicolin (APH)(65).  HU depletes cellular levels of deoxyribonucleoside 
triphosphate (dNTPs) pools by inhibiting the enzyme ribonucleotide reductase, and APH 
induces replicative stress through the inhibition of DNA polymerases (65).  The FA 
pathway is activated in response to replication stress as indicated by an increase in 
FANCD2-Ub levels after replication stress is induced by HU treatment (66).  In addition, 
BRCA1, BRCA2 and FANCD2 have been implicated in stabilizing stalled replication 
forks from meiotic recombination 11 (MRE11) degradation (67,68).  Furthermore, 
FANCD2 can restart replication forks in cooperation with Bloom syndrome helicase 
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(BLM) and independently of FANCI (69,70).  Therefore, FA proteins are activated and 
play a critical role in stabilizing and restarting stalled replication forks to prevent 
replication stress induced genomic instability. 
 
R-loop resolution:  R-loops occur during transcription and are formed as a three-
stranded nucleotide structure with a DNA:RNA hybrid leaving the displaced non-
template strand of DNA single stranded.  The formation of these R-loops can result in 
genomic instability in two ways (54).  First, the generation of single-stranded DNA 
(ssDNA) can provide access to DNA modifying enzymes or repair factors that cause 
DNA damage or mutagenesis (71,72).  Second, R-loops can result in the obstruction of 
the replication machinery leading to hyper-recombination and chromosome fragility (73-
76).  Both FANCA and FANCD2 have roles in resolving R-loops and cells deficient in 
FANCA and FANCD2 accumulate R-loop-induced DNA damage (74).  Furthermore, the 
translocase activity of FANCM was found to prevent R-loop-mediated replication fork 
arrest (77).  In conclusion, FA proteins have been linked to R-loop resolution and 
protection of genomic instability through this mechanism as well. 
 
Cell cycle regulation:  Cell cycle checkpoints control the timing and progression through 
the cell cycle.  When a cell encounters DNA damage brought on by replication stress, the 
ATR kinase is activated as the master regulator of the DNA damage response (78-80).  
ATR is recruited along with its binding partner ATR interacting protein (ATRIP) to 
extended tracts of ssDNA that have been coated with replication protein A (RPA)(81).  
The activation of ATR in S-phase results in the restraint of DNA synthesis and 
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suppression of replication origin firing, thus allowing time for DNA repair.  ATR is 
similarly activated in G2-phase in response to under-replicated or ssDNA.  ATR 
signaling works through activation of checkpoint kinase 1 (CHK1) and results in the 
restraint of cell-cycle progression through the degradation of cell division cycle 25A 
(CDC25A) (80).  CDC25A is a phosphatase that activates cyclin-dependent kinases 
(CDKs).  Therefore, the inactivation of CDKs by CHK1 slows or even arrests the cell 
cycle progression to prevent premature entry into mitosis.  Yet another type of cell cycle 
checkpoint in mitosis is called the spindle assembly checkpoint (SAC), and it is important 
for ensuring that all the chromosomes are attached properly to the mitotic spindle.  If the 
SAC is weakened, it can lead to aneuploidy, cancer, and random chromosome 
segregation (82).   
Importantly, ATR is activated in response to ICL-induced replication fork stalling, 
and subsequently phosphorylates several of the FA proteins including FANCA, FANCE, 
FANCM, FANCI and FANCD2 (34,35,83-87).  In fact, the phosphorylation of FANCI 
and FANCD2 has been implicated as necessary for the subsequent monoubiquitination of 
the ID complex and full activation of the FA/BRCA repair pathway (87,88).   Therefore, 
checkpoint activation and the follow-up repair by the FA pathway are tightly linked and 
an intact FA pathway is required for proper functioning of the checkpoint response to 
ATR.  This was confirmed by several studies in which a FANCD2 deficiency resulted in 
a faulty S phase checkpoint (89-91).  In addition, cells deficient in FANCD2, FANCC, 
and BRCA1 a have faulty G2 phase checkpoint (92,93).  Lastly, several FA patient cell 
lines were tested for SAC defects and all were found to have defects (94). Therefore, 
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failure to maintain checkpoints can be a driver of cancer and genomic instability and it 
may well explain some of the cellular phenotype of FA. 
 
 
The intersection of FA with other DNA repair pathways 
In the canonical FA/BRCA pathway of ICL repair, there is an interplay of additional 
repair pathways that work together to resolve these toxic DNA lesions.  For instance, a 
nuclease normally associated with nucleotide excision repair (NER), XPF/FANCQ, is 
involved in the incisions utilized to unhook the ICL(95).  Similarly, a polymerase, 
polζ, required for translesion synthesis (TLS) is utilized for replication across the ICL 
adduct(8).  Finally, several downstream FA proteins involved in HR are utilized to repair 
the DSB and restore the replication fork to complete the repair(50).  This entwined and 
overlapping use of proteins is representative of the complexity of DNA repair pathways 
that cells have evolved for the repair of DSBs.  
 
Classic non-homologous end joining (C-NHEJ): C-NHEJ repairs of the majority of 
cellular DBS in humans, and is the pathway of choice in G0 and G1 phases of the cell 
cycle when a sister chromatid is not available(96).  C-NHEJ does not require a 
homologous template and can simply religate two ends of broken DNA back together 
with minimal end processing.  The simplicity of this repair mechanism makes it efficient, 
but also error prone because the repair can often incorporate small insertions or deletions 
(indels).  If the DSB occurs in a non-coding region, the resultant repair-mediated indel 
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damage is likely small or irrelevant, however, if an indel occurs in a gene coding region, 
it could have deleterious effects.  C-NHEJ requires the Ku70/Ku80 heterodimer (Ku), 
which binds to DNA termini and then recruits the DNA-dependent protein kinase 
catalytic subunit (DNA-PKcs)(97).  Ku translocates inward from the end, allowing DNA-
PKcs to contact DNA.  This, in turn, activates the DNA-PKcs kinase activity permitting 
via trans autophosphorylation a synapse to form between two bound DNA-PKcs proteins 
on each broken end of DNA(98).  The nuclease, Artemis is then recruited to process the 
DNA ends for repair and a trimeric complex of DNA ligase IV (LIGIV), XRCC4 like 
factor (XLF) and X-ray cross complementing gene 4 (XRCC4) ligates the DNA ends 
together(99). 
It has been proposed that the FA pathway may limit the use of C-NHEJ, and that C-
NHEJ may be aberrantly upregulated in FA-deficient cells.  For instance, ICL 
hypersensitivity is reduced in the FANCC knockout DT40 cell line and the chromosome 
breakage phenotype could be rescued by the additional knockout of Ku (100).  
Furthermore, in the C. elegans fcd-2 (FANCD2) knockout model, ICL sensitivity was 
rescued when lig-4 (LIGIV) was additionally mutated (101).  Moreover, inactivating C-
NHEJ in BRCA1- or BRCA2-deficient cells reduced the frequency of abnormal 
chromosomes (102).  Together these results implicate C-NHEJ as having detrimental 
effects when the FA pathway is deficient.  However, knocking out DNA-PKcs or LIGIV 
in FANCC knockout DT40 cells did not rescue ICL sensitivity (100).  Additionally, a 
knockout of Ku70 in FancA-/- mouse embryonic stem cells did not rescue ICL sensitivity.  
Therefore, there is conflicting evidence for the rescue, via knockout of C-NHEJ pathway, 
of the phenotypes of FA-deficient cells. 
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Alternative Non-homologous End Joining (A-NHEJ): A-NHEJ is a DNA repair 
process for DSBs that does not require a homologous template, but also does not use the 
C-NHEJ proteins such as Ku, XRCC4 or LIGIV.  A-NHEJ, also called microhomology 
mediated end joining (MMEJ) anneals small tracts of microhomology (generally 2 to 20 
bp) flanking the DSB to repair the break (103).  Therefore, repair involves a deletion and 
contains short (micro) stretches of homology at the breakpoint (96,104).  The 
MRE11:radiation sensitive 50 (RAD50):Nijmegen breakage syndrome gene 1 (NBS1) 
complex (MRN complex) DNA polymerase theta, CtBP-interacting protein (CtIP), poly 
(ADP-ribose) polymerase 1 (PARP1), ataxia telangiectasia mutated (ATM) and flap 
endonuclease 1 (FEN1) are all required for — or certainly implicated in— A-NHEJ 
repair (103,105-109).  In the first step of DSB repair by A-NHEJ, PARP1 binds to the 
broken DNA ends and recruits CtIP and MRN complex to resect the DNA ends and 
expose the regions of microhomology (MH)(109,110).  Next, the regions of MH anneal 
and the non-homologous flaps of DNA are cleaved by XPF/ERCC1(111).  Finally, DNA 
polymerase theta fills in the gaps and LIGIII completes the repair (108,112).  Of 
particular interest, A-NHEJ has been implicated in genetic rearrangements and 
chromosomal translocations associated with cancer, and even with reversions of BRCA2 
mutations following PARP inhibitor treatment (113,114).  Additionally, several of the FA 
proteins support A-NHEJ, since knockdown of FANCA, FANCC, FANCD2, FANCE, 
FANCF and FANCM all resulted in reduced A-NHEJ repair (115).  However, 
knockdown of FANCI and FANCL did not reduce A-NHEJ repair, therefore indicating 
that not all FA proteins influence A-NHEJ. 
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HR: HR is considered an error free repair pathway for DSB repair and is typically 
restricted to S/G2 phase of the cell cycle when an intact sister chromatid is available as a 
repair template.  The first step in committing repair to HR is resection of the DNA ends 
creating 3’ ssDNA overhangs.  CtIP phosphorylation by CDKs initiates a complex 
between CtIP, MRN and BRCA1/FANCS in S/G2 to promote resection (116).  The 
ssDNA is then bound by RPA and subsequently displaced by nucleoprotein filaments of 
RAD51/FANCR(117).  RAD51 filament formation and loading onto DNA is aided by 
BRCA2/FANCD1 in conjunction with PALB2/FANCN(118).  Next, RAD51 performs 3’ 
strand invasion, homology search, and D-loop formation with the help of RAD51 
paralogs including RAD51C/FANCO and XRCC2/FANCU(10,119,120).  The D-loop is 
extended by a polymerase and this recombination intermediate can be resolved by 
synthesis dependent strand annealing (SDSA) or through formation of a double Holliday 
junction (HJ) structure.  RAD51C has also been implicated in resolution of 
recombination intermediates in favor of SDSA to prevent long-tract gene 
conversion(121).  SDSA occurs through displacement of the nascent DNA strand 
followed by gap filling and ligation to complete the repair.  However, if SDSA is not 
employed then the D-loop may capture the second end of the break to form a double HJ 
that can be resolved with either crossover or non-crossover products(96).  At an end stage 
of HR, RFWD3/FANCW polyubiquitinates both RPA and RAD51 in DNA repair foci 
through its E3 ubiquitin ligase activity and targets them for removal and 
degradation(4,51,122).  Disruption of any of these FA protein functions in HR results in 
FA. 
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FA and breast cancer susceptibility 
With the importance of FA proteins in DNA repair and genome stability, it is not 
surprising that so many of them are tumor suppressors.  In fact, five of the FA 
downstream proteins with direct roles in HR are hereditary breast and ovarian cancers 
(HBOC) genes including BRCA1, BRCA2, PALB2, BRCA1 interacting protein C-
terminal helicase 1 (BRIP1), and RAD51C (123). In addition, FANCM has been 
implicated as a HBOC gene but seems to be mostly involved in ovarian cancer and head 
and neck SSC (124).   Monoallelic mutation in any one of these six genes results in 
increased cancer risks, therefore HBOC is inherited in an autosomal dominant manner. 
HBOC syndrome has historically been linked to pathogenic variants in BRCA1 and 
BRCA2 but this accounts for less than 10% of all breast cancer cases (125).  However, 
the lifetime risk of breast cancer for a pathogenic variant in BRCA1/2 is between 41 to 
90% emphasizing the importance of these two genes.  The mutation of BRCA1 or 
BRCA2 results in a similar phenotype and they both function in HR.  In proliferating 
cells, HR is the primary mechanism for protecting genomic integrity.  Proteins that 
function at all three levels of the DNA damage response (DDR) to resolve DBS during 
replication by HR are all implicated in HBOC (123,126).  The first level of DDR 
involves the recognition of DNA damage by ATM and ATR.  The second level of DDR 
involves signal transduction by CHK2 and BRCA1, and the third level is initiation of 
repair and involves BRCA2, PALB2, BRIP1, and RAD51(126). 
The main difference between breast cancers associated with BRCA1 and those 
associated with BRCA2 is that BRCA1 mutation carriers predominately develop estrogen 
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receptor (ER)-negative tumors and BRCA2 carriers do not have any tendencies either 
way (127).  BRCA1 and BRCA2 do not physically interact with each other, but PALB2 
bridges them into a common complex.  The BRCA1 coiled-coil domain binds to 
PALB2’s N-terminal coiled-coil domain and BRCA2 binds to PALB2’s C-terminal 
WD40 domain (128-132).  The interaction of PALB2 with BRCA1 is required for the 
recruitment of BRCA2 and RAD51 to DNA damage, and is promoted by BRCA1 
phosphorylation by CHK2 (133).  The BRCA2:PALB2 interaction is essential for the 
chromatin loading of RAD51 (117,134).   Not surprising, PALB2 mutations increase the 
risk of breast cancer by 33% for someone without family history to almost 60% for 
someone with a family history of breast or ovarian cancer (135).  However, PALB2 
mutations occur less frequently than BRCA1 and BRCA2 mutations with an incidence of 
only 1 to 4% of all breast cancer patients having a pathogenic PALB2 mutation.  Overall, 
this suggests that PALB2 plays an important role in tumor suppression by complexing 
with BRCA1 and BRCA2 and facilitating their function in HR. 
 
Summary and project overview 
FA is a complex genetic disease with at least 22 genes working together in the FA/BRCA 
pathway to resolve ICLs, which are highly toxic DNA lesions.  However, the complex 
interactions of these proteins with each other and with other cellular pathways has made 
it difficult to find effective treatments for FA patients.  We set out to generate a set of 
isogenic knockout cell lines in the HCT116 parental line representative of the 3 different 
groups of proteins of the FA pathway: the Upstream/core complex, the ID complex, and 
downstream proteins.  We wanted to use these cell lines to investigate the function of the 
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different protein groups to gain insight into disease heterogeneity resulting from the 
different FA genes and mutations.   I used both recombinant adeno-associated virus 
(rAAV) as well as clustered regularly interspaced palindromic repeat/CRISPR associated 
9 (CRISPR/Cas9)-mediated gene targeting techniques to create isogenic cell lines to 
study the cellular defects of FA knockout cell lines.  FANCA was selected from the 
upstream/core complex because it is the most commonly mutated gene in FA.  Both 
FANCI and FANCD2 were selected from the ID complex, and a double ID2 knockout 
(DKO) cell line was made of the ID complex as well.  Finally, a PALB2/FANCN 
conditional knockout was created to represent the downstream proteins. 
The goal of the first project was to determine if there was a separation of function 
between FANCI and FANCD2 in the replication stress response.  FANCI and FANCD2 
were known to form a heterodimer, be dependent on each other for monoubiquitination, 
and they colocalized on chromatin (38).  However, recent data from the Sobeck 
laboratory had revealed that FANCD2 had additional functions independent of FANCI in 
the restart of stalled replication forks and in interactions with the BLM helicase (69).  
Therefore, we used the newly generated FANCI, FANCD2, and ID2 DKO knockout cell 
lines to further characterize the co-dependent and independent functions of these two 
proteins. 
The goal of the second project was to gain mechanistic insight into FANCN function 
and to characterize FA-associated patient mutations and breast cancer-associated single 
nucleotide polymorphisms (SNPs).  FANCN/PALB2 is an important protein involved in 
HR and interacts closely with BRCA1 and BRCA2 (131).  PALB2 is also a tumor 
suppressor that predisposes humans to breast and ovarian cancer (136,137).  Most patient 
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mutations associated with FA are nonsense mutations creating, in some cases, severely 
truncated protein (138).  However, several breast cancer studies involving next 
generation sequencing of patients have been uncovering variants of unknown significance 
(VUSs) in PALB2 (125,139).  Comparing the function of the known pathogenic FA 
mutations to the VUS mutations could potential confirm if the VUS mutations were 
driver or passenger mutations in breast cancer. 
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FIGURE LEGEND 
Figure 1.  FA proteins in ICL repair.  The 22 FA proteins (FANCA-W) are colored 
according to their group in the FA pathway.  The upstream/core complex is blue, the ID 
complex is purple and the downstream proteins are green.   (A) The FA pathway is 
activated in S-phase by the convergence of two replication forks on an ICL (red lesion).  
Subsequently, the FA core complex composed of FANCA, B, C, E, F, G, L, and M acts 
as an E3 ubiquitin ligase to monoubiquitinate the ID complex composed of FANCI and 
FANCD2.  FANCT is the E2 ubiquitin ligase for the FA core complex.  Once 
monoubiquitinated, the ID complex recruits downstream nucleases to perform the ICL 
unhooking.  (B) Unhooking of the ICL by nucleolytic incision on either side of the ICL 
(orange arrows) is facilitated by FANCP and FANCQ. (C)  Replication across the DNA 
lesion by translesion synthesis (blue arrow) is facilitated by FANCV.  (D) Homologous 
recombination to repair the DNA DSB and complete the repair is performed by 
FANCD1, J, N, O, R, S, U, and W. 
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CHAPTER 2 
 
FANCI AND FANCD2 HAVE COMMON AS WELL AS 
INDEPENDENT FUNCTIONS DURING THE CELLULAR 
REPLICATION STRESS RESPONSE 
 
 
 
 
 
 
 
 
 
This chapter has been accepted for publication in NAR (September 2017) published by 
Oxford University Press. 
Thompson EL, Yeo JE, Lee EA, Kan Y, Raghunandan M, Wiek C, Hanenberg H, 
Schärer OD, Hendrickson EA, and Sobeck A.  FANCI and FANCD2 have common as 
well as independent functions during the cellular replication stress response.  
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SUMMARY 
Fanconi Anemia (FA) is an inherited cancer predisposition syndrome characterized by 
cellular hypersensitivity to DNA interstrand crosslinks (ICLs).  To repair these lesions, 
the FA proteins act in a linear hierarchy: following ICL detection on chromatin, the FA 
core complex monoubiquitinates and recruits the central FANCI and FANCD2 proteins 
that subsequently coordinate ICL removal and repair of the ensuing DNA double-
stranded break by homology dependent repair (HDR).  FANCD2 also functions during 
the replication stress response by mediating the restart of temporarily stalled replication 
forks thereby suppressing the firing of new replication origins.  To address if FANCI is 
also involved in these FANCD2-dependent mechanisms, we generated isogenic FANCI-, 
FANCD2- and FANCI:FANCD2 double-null cells.  We show that FANCI and FANCD2 
are partially independent regarding their protein stability, nuclear localization and 
chromatin recruitment and contribute independently to cellular proliferation.  
Simultaneously, FANCD2 – but not FANCI – plays a major role in HDR-mediated 
replication restart and in suppressing new origin firing. Consistent with this observation, 
deficiencies in HDR-mediated DNA DSB repair can be overcome by stabilizing RAD51 
filament formation in cells lacking functional FANCD2.  We propose that FANCI and 
FANCD2 have partially non-overlapping and possibly even opposing roles during the 
replication stress response. 
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INTRODUCTION 
FA (Fanconi anemia) is an inherited genomic instability disorder that is characterized by 
bone marrow failure and a strong predisposition to cancer, predominantly leukemia and 
squamous cell carcinoma (13,140).  A defining characteristic of FA patient cells is that 
they are highly sensitive to DNA ICL (interstrand crosslink)-inducing agents such as 
MMC (mitomycin C) and DEB (diepoxybutane).  Moreover, FA cells exhibit 
spontaneous chromosomal aberrations that are further exacerbated upon treatment with 
replication inhibiting agents such as HU (hydroxyurea) or APH (aphidicolin) (13,68,141).  
Thus, the FA pathway constitutes an extremely important pathway for the maintenance of 
genome stability.  Currently, 21 different FA genes have been identified and mutations in 
any one of them are sufficient to cause FA (5,8,10). 
The canonical FA pathway of DNA ICL repair is thought to consist of three layers: an 
upstream FA core complex (8 proteins), a central protein heterodimer composed of 
FANCI and FANCD2 (the ID2 complex), and a growing number of downstream proteins 
including FANCD1/BRCA2 (breast cancer associated protein 2) and the FANCR/RAD51 
(radiation sensitive 51) recombinase (5,31).  Repair of the DNA ICLs occurs 
predominately in S-phase when they block the progression of replication forks (142,143).  
Following DNA ICL detection during S-phase, the FA core complex acts as an E3 
ubiquitin ligase that monoubiquitinates FANCI and FANCD2, facilitating their 
recruitment to DNA ICLs on chromatin (144-147).  Subsequently, the chromatin-bound 
ID2 complex coordinates downstream FA scaffolding proteins and nucleases like 
FANCP/SLX4 (synthetically lethal in the absence (X) of Sgs1 4) and 
FANCQ(XPF)/ERCC1 (xeroderma pigmentosum F/excision repair cross-complementing 
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1), respectively, along with BRCA2 and RAD51 to mediate incisions at the DNA ICL, 
followed by HDR (homology dependent repair) of the newly generated DNA DSBs 
(double-stranded breaks) (3,5,31,43-45,95,148). 
Recent studies from our laboratory and others discovered novel roles for FANCD2 during 
the replication stress response (42,67-70,149,150).  Upon replication fork stalling in the 
presence of HU or APH, FANCD2 is recruited to the stalled forks where it performs dual 
roles.  First, it protects the stalled replication forks from nucleolytic degradation (68,149).  
FANCD2 fulfills this role in concert with the upstream FA core complex and several 
downstream FA proteins such as BRCA2 and RAD51 (67,68).  Second, FANCD2 
promotes restart of the stalled replication forks while blocking the firing of new 
replication origins (42,69,150).  Interestingly, the fork restart function of FANCD2 does 
not depend on the FA core complex nor on FANCD2 monoubiquitination (150).  Instead, 
the non-ubiquitinated FANCD2 isoform binds chromatin upon replication fork stalling 
and cooperates with downstream FA factors such as BRCA2 and FANCJ (150) as well as 
non-FA DNA repair proteins such as the BLM (Bloom syndrome) helicase complex (69), 
CtIP (C-terminal interacting protein) (42) and FAN1 (Fanconi-associated nuclease 1) (70) 
to promote fork restart.  Intriguingly, previous findings from our laboratory suggested 
that FANCD2 may fulfill some of its roles during the cellular replication stress response 
independently of FANCI.  Using the Xenopus laevis S-phase extract system, we showed 
that FANCD2 dissociates from FANCI upon replication stress and is recruited to 
chromatin prior to FANCI (151).  Moreover, FANCD2 participates in the assembly of the 
BLM complex independently of FANCI (69).  However, if and how FANCI contributes 
to mechanisms of replication stress recovery is not well understood. 
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To dissect the roles of FANCI and FANCD2 during the replication stress response, we 
generated human FANCI-/-, FANCD2-/- and FANCI-/-:FANCD2-/- knockout cells in an 
isogenic background (the HCT116 cell line).  Analysis of these cells revealed that FANCI 
and FANCD2 act in concert to promote DNA ICL repair, but have partially independent 
roles during the HU- or APH-triggered replication stress response.  Our findings indicate 
that FANCD2 fulfills crucial roles in mediating cellular resistance to HU or APH 
independent of FANCI.  In fact, HU- or APH-triggered cell death in FANCD2-deficient 
cells was FANCI-dependent, suggesting opposing roles of FANCD2 and FANCI during 
cell survival.  Moreover, FANCD2 played a significantly more important role during the 
HDR-mediated, RAD51-dependent mechanisms of replication fork restart and DNA DSB 
repair.  Our results suggest that whereas FANCD2 supports cellular survival and fork 
recovery in the face of APH- or HU-triggered replication stress, FANCI may in fact 
oppose those functions. 
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MATERIALS AND METHODS 
Generation of FANCI-null (I-/-) and FANCD2-null (D2-/-) cells using rAAV-mediated 
gene targeting 
FANCI-null and FANCD2-null HCT116 cells were generated using rAAV (recombinant 
adeno-associated virus)-mediated gene targeting (152).  Conditional and knock-out rAAV 
vectors targeting FANCI exon 10 and FANCD2 exon 12 were constructed using Golden 
Gate cloning and designed as described (152-154).  We targeted FANCD2 exon 12 and 
FANCI exon 10 since these exons both lie within regions encoding conserved protein 
domains associated with heterodimer formation and putative DNA binding (39,155,156), 
and the deletion of these exons should result in frameshift mutations.  The first round of 
targeting with a conditional vector replaced FANCI exon 10 and FANCD2 exon 12 with 
their respective conditional, floxed (flanked by LoxP sites) alleles along with a NEO 
(neomycin) selection cassette, also flanked by LoxP sites.  G418-resistant clones were 
screened by PCR to confirm correct targeting, and Cre (cyclization recombinase) 
transiently expressed from an adenoviral vector (hereafter AdCre) was then used to 
remove the NEO selection cassette as described (152-154).  Retention of the FANCI 
floxed exon 10 and FANCD2 floxed exon 12 in the conditional allele was confirmed by 
PCR.  The second round of FANCD2 gene targeting was performed in the FANCD2flox/+ 
cells with a knock-out rAAV vector in which exon 12 was replaced with a NEO selection 
cassette.  The second round of FANCI gene targeting was performed in the FANCIflox/+ 
cells using the same conditional vector that had been used in the first round of targeting.  
G418-resistant clones were screened by PCR for correct targeting.  Primer sequences for 
all PCR reactions are listed in Supplementary Table S1.  AdCre recombinase was then 
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used to remove both the NEO selection cassette and the conditional allele(s) and resulted 
in viable I-/- and D2-/- clones.  Two independent I-/- clones (labeled as clones #28 and #30) 
and a single D2-/- clone (labeled as clone #39) were generated.  These three clones and 
the clones described below were used interchangeably for most of the subsequent 
experiments.  
CRISPR/Cas9 generation of FANCD2-/- and FANCI-/-:FANCD2-/- (ID2 DKO) cells 
A guide RNA (gRNA) targeting FANCD2 exon 11 was designed so that Cas9 (CRISPR 
associated 9) cleavage would disrupt an endogenous restriction enzyme recognition site 
for BpuEI.  The gRNA was cloned into a CRISPR (clustered regularly interspersed short 
palindromic repeats) /Cas9 plasmid (hSpCas9-2A-Puro/px459) as described (157). WT 
(wild type) HCT116 cells were transfected with the CRISPR/Cas9 plasmid containing the 
gRNA targeting FANCD2 exon 11 using Lipofectamine 3000 (Life Technologies).  Two 
days after transfection, the cells were subcloned, and individual subclones were screened 
for targeting by PCR amplification of exon 11 and by subsequent digestion with the 
restriction enzyme BpuEI (New England BioLabs, Inc.).  Clones that were resistant to 
digestion with BpuEI were TOPO TA cloned (Life Technologies).  Sequencing of the 
TOPO TA clones confirmed targeted bi-allelic disruption that induced frameshifts in 
FANCD2, generating an independent FANCD2-null cell line, designated as clone #29 
(Supplementary Figure S1A).  
In a highly similar fashion FANCI-null cells were also transfected with the CRISPR/Cas9 
plasmid containing the gRNA targeting FANCD2 exon 11 using Lipofectamine 3000 
(Life Technologies).  Subsequent sequencing of the resulting TOPO TA clones confirmed 
targeted bi-allelic disruption that induced frameshifts in FANCD2, generating two 
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independent ID2 DKO (double knockout) cell lines, which were arbitrarily designated as 
clone #1 and clone #2.  Western blot analysis further confirmed that these clones were 
null for FANCD2 and FANCI expression.  Primer sequences for all PCR reactions are 
listed in Supplementary Table S1. 
To demonstrate unequivocally that the reagents (rAAV or CRISPR/Cas9) were irrelevant 
to the resulting phenotypes of the cell lines used in these experiments we also generated 
additional ID2 DKO clones (arbitrarily designated as clones #3 and #4).  These clones 
were created starting with D2-/- clone #29 (CRISPR/Cas9 generated) and D2-/- clone #39 
(rAAV generated) cell lines, respectively.  A gRNA targeting FANCI exon 9 was 
designed so that Cas9 cutting would disrupt an endogenous restriction enzyme 
recognition site for AcuI.  The gRNA was cloned into a CRISPR/Cas9 plasmid 
(hSpCas9(BB)-2A-GFP/ PX458; Addgene plasmid #48138).  This CRISPR/Cas9 plasmid 
co-expresses Cas9 and GFP, and therefore GFP-expressing cells were collected two days 
after transfection by flow cytometry and subcloned.  Subclones were screened for correct 
targeting by PCR amplification of FANCI exon 9 and subsequent digestion with AcuI 
(New England BioLabs, Inc.).  Clones that were resistant to digestion with AcuI were 
TOPO TA cloned and ID2-/- clones #3 and #4 were sequence confirmed for biallelic 
frameshift-inducing mutations (Supplementary Figures S1B, C).  Additionally, western 
blot analyses confirmed that these cell lines did not express any WT FANCI or FANCD2 
protein nor was there any evidence of expression of potential truncated protein products 
(Supplementary Figures S1D, E). In toto, these experiments demonstrated that the cells 
were functional DKOs.  DKO clones #3 and #4 were used exclusively in the experiments 
in which growth of the cell lines was assessed (Fig. 4A). 
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Complementation of D2-/- and I-/- cells 
For expression of hFANCD2, the human FANCD2 transcript 1 cDNA (NM_001018115) 
was optimized by silent mutagenesis, thereby introducing unique restriction enzyme 
recognition sites and removing potential prokaryotic instability motifs, cryptic splice 
sites, RNA instability motifs and polyA sites (Hanenberg et al., manuscript in 
preparation).  The cDNA was purchased from GenScript (Piscataway, NJ).  The D2-/- 
cells were complemented using the optimized human FANCD2 expression cassette that 
was Gateway-cloned into a PiggyBac transposase vector containing a CAG 
(cytomegaloviral/beta-actin/beta-globin) promoter and a NEO selection cassette.  G418-
resistant clones were screened for FANCD2 expression by Western blot analyses. 
The I-/- cells were complemented by performing a third round of gene targeting to "knock 
back in" a functional FANCI allele.  This was accomplished using a CRISPR/Cas9 gRNA 
designed to target immediately 5’ of the LoxP scar left when exon 10 was removed to 
create the I-/- cells.  The FANCI conditional rAAV plasmid containing the FANCI exon 
10 flanked by LoxP sites and a NEO selection cassette, also flanked by LoxP sites was 
used as the donor template.  G418-resistant clones were screened for the knock-in of 
FANCI exon 10, and PCR was used to confirm heterozygous knock-in in two clones.  
The NEO selection cassette was subsequently removed by transient treatment with AdCre 
recombinase, and retention of FANCI exon 10 was confirmed by PCR and DNA 
sequencing.  Restored FANCI expression from the knock-in floxed allele was confirmed 
by Western blot analyses.  Throughout the manuscript, the complemented cell lines are 
designated as (D2-/-:D2, I-/-:I) for D2- and I-null, cells respectively. 
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Finally, I-/- cells overexpressing FANCD2 protein were established by introducing a 
PiggyBac transposon containing the FANCD2 codon-optimized cDNA described above 
into I-/- cells (clone #28).  Two FANCD2-overexpressing FANCI-null cell lines (named 
clones #2 and #12) were identified by Western blot analysis.  These clones were 
designated as I-/-:D2o/e. 
Cell proliferation assay 
WT cells, knockout cells and complemented cells were plated in 6-well tissue culture 
plates according to their plating efficiency: WT cells were plated at 2,500 cells/well, 
complemented cells (D2-/-:D2, I-/-:I) were plated at 5,000 cells/well, and the D2-/-, I-/- and 
ID2 DKO cells were plated at 6,000 cells/well.  Cell counts were performed in triplicate 
4, 6 or 8 days after seeding. 
MMC sensitivity assay 
Cells were plated in triplicate in 96-well plates according to their plating efficiency.  WT 
cells were plated at 750 cells/well, complemented cells (D2-/-:D2, I-/-:I) were plated at 1,000 
cells/well and the D2-/-, I-/- and ID2 DKO were plated at 1,200 cells/well.  On the 
following day, the media was removed and replaced with media containing 0, 5, 10 or 15 
nM MMC.  Cells were allowed to grow for 5 days and cell viability was measured with 
CellTiter96 Aqueous (Promega) according to the manufacturer’s instructions.  The 
viability of MMC-treated cells was normalized to the average viability of the untreated 
control cells for each cell line. 
Cell cycle analysis 
WT cells, knockout cells and complemented cells were plated in 6-well plates according 
to their plating efficiency.  WT cells were plated at 100,000 cells/well, singly-null and 
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complemented cells were plated at 200,000 cells/well and DKO cells were plated at 
320,00 cells/well.  After 24 hr, the media was removed and either untreated media, media 
containing 100 nM APH or media containing 10 nM MMC was added to the cells.  After 
24 hr the cells were harvested and fixed with 1% paraformaldehyde and subsequently 
with cold 70% ethanol.  Fixed cells were washed with PBS (phosphate buffered saline), 
stained (with PBS containing 40 mg/mL propidium iodide; 100 mg/mL RNase A) and 
RNase treated (37° C for 30 min).  Samples were then filtered through a cell strainer cap 
(Corning) and sorted on a BD Accuri C6 instrument and analyzed using FlowJo software 
(V10.1). 
Colony forming assay 
WT cells, null cells and complemented cells were plated in 6-well plates in triplicate 
according to their plating efficiency.  WT cells were plated at 300 cells/well, 
complemented cells (D2-/-:D2, I-/-:I) were plated at 400 cells/well, I-/- cells were plated at 
600 cells/well and D2-/- and ID2 DKO cells were plated at 800 to 1,000 cells/well.  After 
24 hr, the media was removed and DMSO media or media containing 0, 50 100 or 150 
µM HU, or media containing 0, 10, 25 or 50 nM APH was added in triplicate.  Cells were 
incubated for 12 to 14 days, washed in PBS, fixed in 10% acetic acid/10% methanol and 
stained with Coomassie as described (158).  Colonies reaching a minimum size of 50 
cells were counted and normalized to the average colony number in untreated wells. 
DNA repair assays 
The HDR reporter assay was performed with the DR-GFP plasmid as described (159). 
The DR-GFP reporter plasmid contains two mutated GFP genes in tandem, and one of 
the mutated GFP genes contains an I-SceI restriction enzyme recognition site.  If 
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HDR/gene conversion between the two mutated GFP genes is used to repair the DSB 
induced by I-SceI digestion, then GFP expression is restored. 
The A-NHEJ (alternative non-homologous end joining) reporter assay was performed 
with the pEJ2-GFP plasmid as described (104,154).  The pEJ2-GFP reporter plasmid 
contains a GFP expression cassette interrupted by an I-SceI restriction enzyme site and 
three stop codons flanked by 8 bp of microhomology.  If microhomology-mediated repair 
(i.e., A-NHEJ) is used to repair the DSB induced by I-SceI restriction enzyme digestion, 
then GFP expression is restored.  For both DNA repair assays, three plasmids including 
the reporter plasmid (DR-GFP or pEJ2-GFP), an I-SceI expression plasmid, and a 
mCherry expression plasmid (which was used as a transfection control) were co-
transfected into the cells using Lipofectamine 3000 (Life Technologies).  72 hr after 
transfection, the cells were fixed with 4% paraformaldehyde and sorted by FACS 
(fluorescence-activated cell sorting).  The DNA repair efficiencies were determined as 
the number of dual GFP-positive and mCherry-positive cells divided by the number of 
mCherry-positive cells.  The values were normalized to the repair efficiency observed in 
WT cells.  For the RS-1 treatment during the HDR assay, 7.5 nM RS-1 was added to the 
media 2 hr prior to plasmid transfection.  Fresh media containing 7.5 nM RS-1 was added 
again 24 hr after transfection. 
Preparation of whole cell extracts (WCE), as well as nuclear, and chromatin 
fractions 
For WCE (whole cell extract) preparation, cells were washed in PBS, resuspended in 
lysis buffer (10 mM Tris pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 
1 mM EDTA, 1 mM DTT, 0.5 mg/ml pefabloc protease inhibitor) and incubated on ice 
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for 20 min.  Cell extracts were centrifuged for 5 min at 10,000 rpm, and the supernatant 
was used for further analysis.  Nuclear and chromatin fractions were prepared using a 
Subcellular Protein Fractionation Kit (Thermo Scientific). 
Antibodies 
The following antibodies were used for Western blotting and immunofluorescence 
assays: anti-FANCD2 (Santa Cruz, sc-20022 and Abcam, ab2187), anti-FANCI (Bethyl 
Laboratories, A300-212), anti-FANCI (160), anti-Ku86 (Santa-Cruz, sc-5280), anti-CtIP 
(161), anti-RAD51 (Santa Cruz sc-8349), anti-GAPDH (Genetex, GTX627408), anti-
tubulin (Abcam, ab7291), anti-g-H2AX (Bethyl Laboratories, A300-081), anti-phospho-
p53 (Ser15) (Santa Cruz, sc-11764-R), anti-p21 (Santa Cruz, sc-397) and anti-PCNA 
(Calbiochem, PC10).  
Immunoblotting 
Protein samples were separated on gradient gels and transferred to Immobilon P 
membranes (Millipore).  After blocking in 5% milk, the membranes were incubated with 
the following primary antibodies: FANCD2 (1:1,000), FANCI (1:2,000), Ku86 (1:5,000), 
GAPDH (1:5,000), CtIP (1:400), PCNA (1:5000), g-H2AX (1:10,000), phospho-p53 
(1:1,000), and p21 (1:400).  A horseradish peroxidase-conjugated rabbit secondary 
antibody (Jackson Laboratories) or a mouse secondary antibody (Biorad) were used at 
dilutions of 1:10,000 and 1:3,000, respectively.  Protein bands were visualized using an 
EL Plus system (Amersham). 
Immunofluorescence analysis of DNA repair foci 
Indirect immunofluorescence was carried out essentially as described (162).  The primary 
antibodies used were: FANCD2 (Abcam, ab2187, 1:4,000), CtIP (mouse monoclonal, 
34	  
	  
1:400), and RAD51 (Calbiochem, PC130, 1:1000).  The secondary antibodies used were: 
Alexa Fluor 594-conjugated goat anti-rabbit (1:1,000) and Alexa Fluor 488-conjugated 
goat anti-mouse (1:1000; Molecular Probes).  For statistical analysis of nuclear foci 
formation, images were taken using a Leica DM LB2 microscope with a Hamamatsu 
Orca-ER camera.  Quantification of CtIP and RAD51 foci was carried out using ImageJ. 
DNA fiber assay 
We used a vetted DNA fiber protocol (163).  Moving replication forks were labeled with 
DigU (digoxigenin-dUTPs) for 25 min and then with BioU (biotin-dUTPs) for 40 min.  
To allow efficient incorporation of the dUTPs, a hypotonic buffer treatment (10 mM 
HEPES, 30 mM KCl, pH 7.4) preceded each dUTP-labeling step.  To visualize labeled 
fibers, cells were mixed with a 10-fold excess of unlabeled cells, fixed and dropped onto 
slides.  After cell lysis, DNA fibers were released and extended by tilting the slides.  
Incorporated dUTPs were visualized by immunofluorescence detection using anti-
digoxigenin-Rhodamine (Roche) and streptavidin-Alexa-Fluor-488 (Invitrogen).  Images 
were captured using a Deltavision microscope (Applied Precision) and analyzed using 
Deltavision softWoRx 5.5 software.  All DNA fiber results shown are the means of two 
or three independent experiments (using 300 DNA fibers/experiment).  Error bars 
represent the standard error of the mean (SEMS) and the significance was determined by 
t-test and Mann-Whitney tests.  Statistical significance at P < 0.05, P < 0.01, and P < 
0.001 are indicated as *, **, ***, respectively. 
Molecular DNA combing assay 
We carried out DNA combing assays (164) as described in the manufacturer’s protocol 
(Genomic Vision), with some modifications as described below.  Briefly, moving 
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replication forks were labeled with 5-chloro-20-deoxyuridine (CldU, Sigma-Aldrich) for 
20 min and then with 5-iodo-20-deoxyuridine (IdU, Sigma-Aldrich) for 40 min.  To 
achieve lysis, the cells were embedded in low-melting agarose (Bio-Rad) followed by 
incubation in DNA extraction buffer (0.5M MES buffer, pH 5.5, Millipore).  To stretch 
the DNA fibers, silanized coverslips (22 mm X 22 mm, Genomic Vision) were dipped 
into the extracted DNA buffer for 13 min and then pulled out a constant speed at 300 
um/s.  The coverslips were then baked at 60  for 4 hr and incubated with 2.5 M HCl for 
denaturation.  Incorporated CldU and IdU were visualized using a rat anti-BrdU antibody 
(dilution 1:50 ~ 1:100 for CldU, Abcam) or a mouse anti-BrdU antibody (1:10 ~ 1:50 for 
IdU, Becton Dickinson).  Slides were fixed with 4% paraformaldehyde in PBS and 
incubated with Alexa Fluor 488-conjugated goat anti-rat antibody (dilution 1:100 ~ 
1:200, Molecular Probes/Thermo Fisher) or Alexa Fluor 568-conjugated goat anti-mouse 
antibody (dilution 1:100 to 1:200, Molecular Probes/Thermo Fisher) for 1 hr.  Finally, 
coverslips were mounted with ProLong Gold Antifade Reagent (Molecular Probes) and 
stored at -20 .  DNA fiber images were captured using LSM880 microscope (Carl 
Zeiss). 
All DNA combing results shown are the means of two or three independent experiments 
(using 300 DNA fibers/experiment).  Error bars represent the standard error of the mean 
(SEMS) and the significance was determined by a t-test.  Statistical significance at P < 
0.05, P < 0.01, and P < 0.001 are indicated as *, **, ***, respectively. 
Statistical analysis 
Error bars represent the standard deviation of the mean and p-values were determined 
using a Student’s t-test.  Statistical significances at P < 0.05, P < 0.01, and P < 0.001 
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were indicated as *, ** and ***, respectively.  A summary of all P-values for results 
shown in Figures 3 to 6 is provided in Supplementary Table S2. 
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RESULTS 
Generation and complementation of human FANCI, FANCD2 and FANCI:FANCD2 
DKO knockout cell lines 
To knock out the FANCD2 and FANCI genes in the parental HCT116 cell line, a 
conditional knockout approach was used.  We chose this approach since all patient-
derived cells from complementation groups FA-D2 and FA-I described to date exhibit 
residual expression of FANCD2 (165) or FANCI (145,166,167), respectively, which 
raised the possibility that FANCD2 and/or FANCI might be essential in human somatic 
cells.  The conditionally null cell lines were created using recombinant adeno-associated 
virus (rAAV) gene targeting techniques, as described (Figure 1)(152-154,168).  Thus, the 
FANCD2-/- cell line (D2-/- clone #39) was generated using two rounds of rAAV gene 
targeting, first with the conditional vector (Figure 1A) and second with the knockout 
vector (Figure 1B).  To unequivocally demonstrate that the technology utilized to 
generate the knockout cell lines was irrelevant to the cell's subsequent phenotypes we 
also generated (described in the Materials and Methods) a second FANCD2 knockout 
clone (D2-/- clone #29) utilizing CRISPR/Cas9 technology. 
Similarly, the FANCI-/- cell lines (I-/-) were generated using two rounds of targeting with a 
conditional rAAV vector (Figure 1A).  In this fashion, two independent FANCI-null 
clones were obtained and designated as clone #28 and clone #30, respectively.  These 
experiments demonstrated that our original concern about the possibility of these genes 
being essential was unwarranted as null cell lines corresponding to both genes were 
readily isolated. 
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Deletion of the targeted exons was confirmed by PCR amplification across the deleted 
exon region resulting in significantly smaller PCR products for the null alleles (Figure 
2A).  Since the FANCD2 exon 12 was targeted with two different rAAV vectors that 
were designed to generate different-sized deletions the D2-/- genotype could consequently 
be confirmed by the appearance of the two differently-sized PCR products (“Null” bands 
of 365 and 151 bp; Figure 2A).  Confirmation of the I-/- genotype was achieved by PCR 
amplification across FANCI exon 10 resulting in a single PCR band representing deletion 
of exon 10 on both alleles (“Null” band of 252 bp; Figure 2A). 
To generate the FANCD2-/-:FANCI-/- doubly-null cell line (ID2 DKO), we utilized 
CRISPR/Cas9 gene targeting to knock out FANCD2 in the I-/- cell line (Figure 2 B-D).  A 
guide RNA was designed to target the Cas9 endonuclease to cleave within an endogenous 
restriction enzyme recognition site (BpuEI) in FANCD2 exon 11.  Subsequently, 
mutagenic insertion or deletions (indels) created by end joining repair of the 
CRISPR/Cas9-mediated DSB in FANCD2 were detected by disruption of the BpuEI 
restriction enzyme site (Figure 2B).  Screening of targeted clones revealed two 
independent clones with complete resistance to digestion with BpuEI, indicating bi-allelic 
disruption of FANCD2 in the I-/- cells (Figure 2C).  Sequence analysis of the targeted 
region was used to confirm that both clones had CRISPR/Cas9-induced bi-allelic 
frameshift mutations in FANCD2, resulting in two independent viable ID2 DKO cell 
lines (Figure 2D; arbitrarily designated as clones #1 and #2, respectively).  To once again 
demonstrate that the knockout technology used to construct the cell lines was irrelevant 
to their biological phenotypes, we also generated (described in the Materials and 
Methods) two additional ID2 DKO clones in a converse fashion to that described above, 
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thus inactivating FANCI in a FANCD2-null cell line.  These clones were arbitrarily 
designated as ID2 DKO clones #3 and #4, respectively. 
Western blot analysis of WCE prepared from WT, D2-/-, I-/-, and ID2 DKO cells 
confirmed that the genetically-null cells lacked expression of FANCD2, FANCI or both 
proteins, respectively, compared to the WT cells (Figure 3A, B and Supplementary 
Figures S1D, S1E).   Complementation of the D2-/- cell line (D2-/-:D2) was accomplished 
by stable genome integration of a constitutively expressed, sequence-optimized FANCD2 
cDNA via a PiggyBac transposon vector.  Interestingly, we were unable to follow this 
complementation strategy in I-/- cells, since these cells did not maintain stable FANCI 
protein expression of a constitutively expressed FANCI cDNA (regardless of whether the 
expression vector was a transposon, retrovirus or plasmid; data not shown), similar to 
previous reports (167,169).  Instead, complementation of the I-/- cell line was 
accomplished by a third round of CRISPR/Cas9-mediated knock-in of the conditional 
exon 10 allele, resulting in reversion of the FANCI-/- genotype to a FANCIflox/- genotype 
(designated as I-/-:I).  Western blot analysis of the complemented cell lines showed that 
the D2-/-:D2 and I-/-:I cells exhibited WT-like protein expression of FANCD2 and FANCI, 
respectively (Figure 3A, B).  In agreement with previous reports that FANCD2 and 
FANCI are interdependent for their DNA damage-inducible monoubiquitination 
(87,145,151,166), HU treatment triggered FANCD2Ub and FANCIUb formation in WT 
cells, but not in I-/- or D2-/- cells, respectively (Figure 3A, B).  Importantly, FANCD2Ub 
and FANCIUb formation was fully restored in D2-/-:D2 and I-/-:I cells (Figure 3A, B), 
demonstrating a functional restoration of the key monoubiquitination step in both 
complemented cell lines. 
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FANCD2 and FANCI are partially independent for their protein stability, nuclear 
import and chromatin recruitment and contribute separately to normal cell 
proliferation 
Several previous studies suggested that the FANCD2 and FANCI proteins stabilize one 
another, while other reports did not (87,145,151,166).  To address this question, we 
compared the expression levels of FANCD2 and FANCI in WT, I-/- or D2-/- cells that 
were untreated or treated with 2 mM HU.  FANCD2 protein levels in WCEs were 
reduced by approximately 50% in I-/- cells compared to WT cells regardless of the 
absence or presence of HU-induced DNA damage (Figure 3C).  Similarly, FANCI 
protein levels were reduced by approximately 60% in untreated or HU-treated D2-/- cells 
compared to WT cells (Figure 3C).  Thus, approximately half of the cellular FANCD2 
and FANCI protein levels remain unaffected in the absence of the respective binding 
partner. 
FANCD2 and FANCI each contain nuclear localization signals and can bind chromatin 
constitutively; moreover their chromatin binding increases after replication stress 
induction (66,145,151,170,171).  To determine if FANCD2 and FANCI rely on each 
other for their nuclear import, we analyzed nuclear extracts from WT, D2-/- or I-/- cells 
that were untreated or HU-treated for 6 or 24 hr.  In untreated conditions, D2-/- and I-/- 
cells contained nuclear protein levels of FANCI and FANCD2, respectively, that were 
comparable to those in WT cells (Figure 3D, compare lanes 1 to 3).  In contrast, while 
HU treatment stimulated a strong increase in nuclear FANCD2 and FANCI protein levels 
in the WT cells (Figure 3D, lanes 1, 4 and 7), no such increase was observed in I-/- cells 
(Figure 3D, lanes 6 and 9) or D2-/- cells (Figure 3D, lanes 5 and 8).  These results suggest 
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that nuclear accumulation of FANCD2 and FANCI occurs independently in unperturbed 
conditions, but becomes interdependent during replication stress. 
To determine the extent to which FANCD2 and FANCI chromatin recruitment occurs 
interdependently, we prepared chromatin factions from WT, D2-/- or I-/- cells that were 
either untreated or HU-treated for 6 or 24 hr.  In WT cells, FANCD2 and FANCI were 
robustly bound to chromatin and accumulated further during the course of HU treatment 
(Figure 3E, lanes 1, 4, and 7).  In contrast, no chromatin-bound FANCI was detectable in 
the D2-/- cells regardless of the presence or absence of HU (Figure 3E, lanes 2, 5 and 8).  
Interestingly, a small amount of residual chromatin-associated FANCD2 was detected 
reproducibly in untreated or HU-treated I-/- cells (Figure 3E, lanes 3, 6, and 9, red 
arrows).  Since FANCD2 cannot become monoubiquitinated in I-/- cells (Figure 3B, C), 
this finding demonstrates that the non-ubiquitinated FANCD2 isoform retains chromatin 
binding ability in the absence of FANCI.  Thus, although FANCD2 and FANCI are 
monoubiquitinated in a strictly interdependent manner, they are partially independent of 
one another regarding their protein stability, nuclear accumulation and chromatin 
recruitment, hinting at separate cellular functions of the two factors   .  To further test 
this, we compared cellular growth between the WT or WT-like D2-/-:D2 and I-/-:I cell lines 
and the I-/-, D2-/- and ID2 DKO knockout cells in a cell proliferation assay.  The three 
knockout cell lines exhibited significantly reduced cellular growth rates compared to the 
WT, D2-/-:D2 and I-/-:I cells, indicating that FANCD2 and FANCI both contribute to 
cellular proliferation (Figure 4A).  Strikingly, the cellular growth rates of the three 
knockout cell lines were also significantly different from one another, with decreasing 
colony formation abilities in the following order: I-/- > D2-/- > ID2 DKO cells.  These 
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results indicate that FANCD2 and FANCI have partially non-overlapping roles to 
promote cellular proliferation in otherwise unperturbed conditions. 
FANCD2 and FANCI act in concert during ICL repair 
A hallmark of FA is the cellular hypersensitivity to ICL-inducing agents such as MMC 
(172), accompanied by a persistent G2/M cell cycle arrest due to a failure to arrest (and 
repair) cells at the intra-S-phase checkpoint (13,91,145,173).  To test if FANCD2 and 
FANCI cooperate to promote cellular resistance to DNA ICLs, we performed a survival 
assay.  The cells were plated with increasing concentrations of MMC and the cell 
viability was measured after 5 days.  D2-/-, I-/- and ID2 DKO cells were highly and 
equally sensitive to even the lowest MMC concentration (5 nM) when compared to the 
WT cells; moreover the complemented D2-/-:D2 and I-/-:I cells exhibited WT-like MMC 
resistance, further indicating full functional complementation of these cells (Figure 4B).  
To analyze the cell cycle profiles of FANCD2- and/or FANCI-deficient cells in 
unperturbed and ICL-treated conditions, asynchronous cell populations were either 
untreated or treated with 10 nM MMC for 24 hr, followed by staining with propidium 
iodide and FACS analysis.  In untreated conditions, the D2-/-, I-/- and ID2 DKO cells 
exhibited unaltered cell cycle profiles compared to the WT cells or their complemented 
counterparts (Figure 4C).   In contrast, MMC treatment triggered a robust and 
comparable G2/M arrest in D2-/-, I-/- and ID2 DKO cells compared to WT, D2-/-:D2 or I-/-:I 
cells (Figure 4C, D and Supplementary Figure S2).  Thus, FANCD2 and FANCI act in 
concert to promote cellular resistance to DNA ICLs. 
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FANCD2 negatively regulates FANCI to promote cellular resistance to APH or HU  
FANCD2 and FANCI accumulate on S-phase chromatin in response to the replication 
inhibitors APH or HU (66,151,170,174).  Moreover, the Kupfer laboratory recently 
demonstrated that FANCD2-deficient patient cells are sensitive to HU treatment (174).  
To investigate if FANCD2 and FANCI both contribute to cellular APH or HU resistance, 
WT, D2-/-, D2-/-:D2, I-/-, I-/-:I and ID2 DKO cells were plated and either left untreated or 
treated with increasing doses of HU (50, 100 or 150 µM) or APH (10, 25 or 50 nM).  
Colony formation of each cell line was determined after 12 to 14 days.  The D2-/- cells 
exhibited a strikingly increased, dose-dependent hypersensitivity to both HU and APH 
compared to WT cells (Figure 5A, B and Supplementary Figures S3A, B).  In contrast, 
the I-/-cells did not exhibit any HU or APH hypersensitivity compared to WT cells, 
indicating that FANCI is dispensable for the cellular resistance to HU or APH.  
Strikingly, the ID2 DKO cells did not exhibit HU or APH sensitivity either, 
demonstrating that the depletion of FANCI restores the cellular resistance to these 
replication stressors in the absence of FANCD2 (Figure 5A, B and Supplementary 
Figures S3A, B).  To further investigate this, we set out to analyze the cellular replication 
stress response in WT, D2-/-, I-/- or ID2 DKO cells in more detail.  Since FANCD2 is 
predicted to protect stalled replication forks from collapsing into DNA DSBs (68-70), we 
asked if spontaneous or HU-triggered DNA DSB levels differed between D2-/- cells and 
the WT, I-/- or ID2 DKO cells.  Cells were untreated or treated with doses of low HU (500 
µM) or high HU (2 mM) for 24 hr and WCEs were analyzed for the DNA DSB markers 
γ-H2AX and phospho-RPA2 (replication protein A; phosphorylated at serines 4 and 8).  
We did not observe any differences in the spontaneous or HU-triggered γ-H2AX or 
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phospho-RPA2 levels between the four cell lines, indicating that the DNA DSB burden 
per se is not elevated in cells lacking FANCD2 and/or FANCI (Figure 5C, D).  Next, we 
asked if the chromatin recruitment of HDR repair proteins during replication stress was 
differently affected in D2-/- cells compared to WT, I-/- or ID2 DKO cells.  CtIP, a key 
HDR factor required for replication restart and DNA DSB repair, relies on FANCD2 for 
its own chromatin recruitment (42,175,176).  To analyze CtIP chromatin binding and 
CtIP relocalization into nuclear DNA repair foci, cells were left untreated or treated with 
2 mM HU for 20 hr, followed by chromatin blotting or immunofluorescence analyses.  In 
support of our previous findings, CtIP recruitment to chromatin and into DNA repair foci 
was severely reduced in untreated and HU-treated D2-/- cells compared to the WT cells 
(Figure 5E, F and Supplementary Figure S4).  However, the I-/- and ID2 DKO cells 
exhibited CtIP recruitment defects comparable to those observed in the D2-/- cells, 
suggesting that CtIP recruitment to stalled or collapsed replication forks relies on both 
FANCD2 and FANCI.  We next analyzed the HU-triggered foci recruitment of RAD51, a 
second key HDR protein that forms protein-DNA filaments and is required for replication 
fork recovery and HDR repair of DNA DSBs.  As expected, WT cells showed 
spontaneous RAD51 foci formation (10% cells), which increased significantly following 
2 mM HU treatment for 20 hr (65% cells).  Somewhat unexpectedly, the D2-/-, I-/- and 
ID2 DKO cells were fully competent for RAD51 foci formation before and after HU 
treatment (Figure 5G and Supplementary Figure S5), indicating that neither FANCD2 nor 
FANCI are crucial for the relocalization of RAD51 to HU-induced DNA repair foci.  
Supportive of this idea, we observed no difference in RAD51 foci formation in the 
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untreated or HU-treated FA-D2 patient cell line, PD20, compared to its complemented 
counterpart, the PD20+D2 cell line (Supplementary Figure S6).  
In addition to its role in DNA repair, FANCD2 has also been implicated in the so-called 
DNA damage tolerance (DDT) pathway that allows for cellular survival in the face of 
persistent DNA damage and replication stress (177,178).  A key activation step of this 
pathway is the monoubiquitination of PCNA (proliferating cell nuclear antigen), which in 
turn recruits DNA TLS (translesion synthesis) polymerases to promote continuous, albeit 
mutagenic, replicative DNA synthesis.  Recent studies showed that HU-induced PCNA 
monoubiquitination (PCNAUb) occurs in a FANCD2-supported manner to promote 
cellular HU resistance (174,179).  To test if PCNAUb formation is affected differently in 
D2-/- cells compared to WT, I-/- or ID2 DKO cells, cells were left untreated or treated with 
2 mM HU for 20 hr, followed by a chromatin blotting analysis.  As expected, D2-/- cells 
exhibited a decreased spontaneous and HU-induced PCNAUb formation; however, we 
observed similarly reduced PCNAUb levels in the I-/- or ID2 DKO cells (Figure 5H), 
suggesting that HU-induced PCNA monoubiquitination relies on both FANCD2 and 
FANCI.  
Since none of these analyses adequately explained the unique hypersensitivity of D2-/- 
cells to HU and APH we next assessed the status of activated p53 in all of the cell lines.  
WT and all three knockout cell lines were untreated or treated with APH for 20 hr, 
followed by analysis of phospho-p53 (S15) and — as a relevant downstream p53 target 
— cellular p21 protein levels.  Strikingly, phospho-p53 and p21 levels were highly 
elevated in untreated and APH-treated D2-/- cells, but not in the WT, I-/- or ID2 DKO cells 
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(Figure 5I).  These findings suggest that FANCD2 may protect cells from FANCI-
mediated, replication stress-induced cell death. 
FANCD2 promotes the restart of stalled replication forks independently of FANCI 
FANCD2 functions to restart HU or APH-stalled replication forks, while simultaneously 
suppressing the firing of new replication origins (42,69,70,150).  To test if FANCI shares 
these functions, we monitored replication events in WT, D2-/-, I-/- and ID2 DKO cells 
with a dual-labeling DNA fiber assay (69,163).  Replication tracts were first labeled with 
DigU (red label) for 25 min, then left untreated or treated with 30 µM APH for 6 hr to 
cause replication fork arrest, followed by a second labeling with BioU (green label) for 
40 min (Figure 6A).  Different from the efficient fork restart in WT cells, the proportion 
of replication forks competent for restart after APH treatment was severely reduced in 
D2-/- cells (45% vs 85%, p < 0.01) (Figure 6B).  In parallel, the proportion of newly 
originated replication tracts (BioU label only) increased significantly (two-fold; p < 0.01) 
in D2-/- cells compared to WT cells (Figure 6C).  In contrast, we observed much milder 
replication restart defects in the I-/- cells (63%; p < 0.05) and the ID2 DKO cells (54%; p 
< 0.01), accompanied by a lower number of newly fired replication origins (I-/- cells: 1.4-
fold, p < 0.05; ID2 DKO cells: 1.6-fold, p < 0.01) compared to the D2-/- cells (Figure 6B, 
C).  Importantly, the replication restart efficiencies were significantly different between 
the three knockout cell lines, with an increase in restart efficiency in the order: D2-/- < 
ID2 DKO < I-/- cells (Figure 6B).  To further validate these findings in the presence of a 
second replication fork stalling agent, HU, we performed a technically improved DNA 
replication fork restart analysis using DNA combing (164). Moving replication forks 
were labeled with CldU (green label) for 20 min, then left untreated or treated with 4 mM 
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HU for 4 hr to cause replication fork arrest, followed by a second labeling with IdU (red 
label) for 40 min (Figure 6D).  Comparable to what we observed following APH-
mediated fork stalling, WT cells exhibited efficient fork restart following HU treatment, 
whereas the proportion of restarted replication forks after HU treatment was significantly 
reduced in D2-/- cells (68%, p < 0.01) (Figure 6E).  Moreover, we observed milder 
replication restart defects in the I-/- cells (81%; p < 0.05) and in the ID2 DKO cells (71%; 
p < 0.01). 
These findings indicate that FANCD2 plays a more crucial role than FANCI during 
replication fork restart and the inhibition of new origin firing.  Moreover, the fact that 
FANCI depletion in D2-/- cells improved these cells’ ability to restart replication forks 
and suppress new origin firing, particularly after APH treatment, provocatively suggests 
that FANCI may have an inhibitory effect on both mechanisms in the absence of 
FANCD2. 
Considering that non-ubiquitinated FANCD2 retains weak chromatin binding activity in 
I-/- cells (see Figure 3E), we then hypothesized that the few remaining chromatin-bound 
FANCD2 molecules may still be functional and capable of promoting replication fork 
restart in the absence of FANCI.  If this were indeed the case, it should be possible to 
completely alleviate the replication fork restart defect in I-/- cells by increasing the 
amount of chromatin-bound FANCD2.  To test this, we overexpressed FANCD2 in I-/- 
cells (I-/-:D2o/e, Figure 7A), resulting in chromatin-bound, non-ubiquitinated FANCD2 
levels comparable to those observed for chromatin-bound, monoubiquitinated FANCD2 
in WT cells, before and after HU treatment (Figure 7B).  WT, D2-/- and I-/- cells, as well 
as two different I-/-:D2o/e cell clones, were then analyzed for their replication fork restart 
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efficiencies following HU treatment using the DNA combing assay.  Strikingly, unlike 
the I-/- cells that were moderately defective for replication fork restart (81%, p < 0.05), 
both  I-/-:D2o/e cell clones were completely proficient in restarting HU-stalled replication 
forks, comparable to the WT cells (Figure 7C).  These results indicate that non-
ubiquitinated, chromatin-bound FANCD2 is fully competent to promote replication fork 
restart in the absence of FANCI.  
Stabilizing RAD51 nucleoprotein filaments restores HDR-mediated DNA DSB 
repair in cells lacking functional FANCD2 
Cells can utilize HDR to repair DNA DSBs (5,50), including those created by the 
unhooking of a DNA ICL lesion (142,143).  In addition, a growing number of HDR 
factors have been implicated in promoting replication fork recovery in concert with 
FANCD2 (42,67-70,83,150), suggesting that the restart machinery utilizes HDR-related 
mechanisms to restart DNA synthesis at a stalled fork.  To investigate the roles of 
FANCD2 and FANCI in HR-mediated DNA DSB repair we utilized a well-established 
reporter plasmid DNA repair assay (159). In this assay, a plasmid containing two non-
functioning GFP genes in tandem is transfected into the cells.  One non-functioning GFP 
gene contains an I-SceI restriction enzyme recognition site and the other is truncated at 
both the 5’- and 3’-ends.  Digestion of the plasmid with I-SceI creates a DNA DSB in the 
non-functional GFP gene that can subsequently use the truncated GFP gene as template 
to restore GFP expression by homology-directed gene conversion repair.  As a control for 
this assay, we included the RAD54B-/-/- HCT116 cell line that has an established HDR 
defect (180,181).  The D2-/- cells were severely deficient in HDR-mediated DNA DSB 
repair (34% of WT), a level that was comparable to the RAD54B-/-/- cells (Figure 8A).  In 
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contrast, the I-/- and ID2 DKO cells exhibited much milder HDR repair defects (62% and 
56% of WT, respectively (Figure 8A)).  These results indicate that (i) FANCD2 has a 
more important role than FANCI in HDR-mediated DNA DSB repair and — surprisingly 
that — (ii) FANCI opposes HDR-mediated DNA DSB repair in the absence of FANCD2. 
FANCD2 was proposed to recruit the HDR factor RAD51 to chromatin during replication 
stress and to stabilize RAD51 nucleoprotein filaments that are crucial to promote HDR 
mechanisms of replication fork recovery and DSB repair (68,182).  Thus, we wanted to 
ask if the HDR repair deficiency observed in cells lacking functional FANCD2 can be 
overcome by stabilizing RAD51 filament formation.  To this end, we repeated the GFP 
HDR assay described above in WT, D2-/-  I-/- and ID2 DKO cells in the absence or 
presence of a RAD51 filament stabilizing agent, RS-1 (183). In the presence of RS-1, all 
three knockout cell lines restored their HDR repair efficiency to a level comparable to the 
untreated WT cells (Figure 8B).  Taken together, these findings support a current model 
(68,182) in which chromatin-bound FANCD2 plays a crucial role in stabilizing RAD51 
filament formation during HDR-mediated DNA repair and, consequently, replication fork 
recovery. 
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DISCUSSION 
In this study, we analyzed the functions of FANCD2 and FANCI during DNA 
replication, using isogenic knockout cell lines.  Our results suggest that FANCD2 and 
FANCI fulfill partially independent and at times opposing roles in the cellular replication 
stress response (Figure 9).   
A novel cell model to study common and independent roles of FANCD2 and FANCI 
Our model system provides unique advantages compared to the use of FA patient cells or 
siRNA knockdown approaches.  First, patient-derived FA-D2 and FA-I cell lines are 
derived from different genetic backgrounds and exhibit residual FANCD2 and FANCI 
protein expression (145,165,166); second, siRNA-mediated knockdown approaches 
cannot completely or permanently eliminate protein expression (42,145,150,166).  In 
contrast, our system allowed for a functional dissection of the roles of FANCD2 and 
FANCI in identical genetic background settings and in the complete absence of any 
FANCD2 and/or FANCI protein expression.  On a technical note, but similar to previous 
reports (167,169), our attempts to complement I-/- cells with a stably integrated FANCI 
cDNA were unsuccessful due to the rapid loss of FANCI expression, strongly suggesting 
that cells may not tolerate FANCI expression from a random genomic locus or, more 
likely, that FANCI overexpression is toxic (see also below). 
Based on the fact that all known FA-D2 or FA-I patient cell lines have residual FANCD2 
and FANCI (respective) expression (145,165,166), we predicted that the complete loss of 
one or both proteins may be lethal.  However, the D2-/-, I-/- and ID2 DKO cell lines were 
viable, indicating that neither FANCD2 nor FANCI are essential in human somatic cells; 
needless to say, however, these experiments do not rule out important developmental 
51	  
	  
roles for either of these genes, a likelihood that is consistent with the developmental 
abnormalities often observed in FA patients.  While not formally essential, both proteins 
contribute to cellular proliferation.  Importantly, the fact that ID2 DKO cells proliferated 
significantly slower than either of the singly-null cells demonstrates that FANCD2 and 
FANCI have (at least) partially non-overlapping roles during normal cellular 
proliferation.  Consistent with this idea, in the Xenopus system the ID2 dimer dissociates 
upon activation in S-phase, followed by consecutive recruitment of FANCD2 and FANCI 
to S-phase chromatin (151).  Furthermore, FANCD2 acts independently of FANCI to 
assemble and recruit the BLM helicase complex to replicating chromatin (69). 
A separation-of-function between FANCD2 and FANCI is further supported by our 
finding that approximately 40 to 50% of either protein is stably expressed in absence of 
the respective other partner, in agreement with some previous studies (87,145,166).  
Interestingly, nuclear accumulation of FANCD2 and FANCI occurred independently of 
one another in unperturbed conditions.  This suggests that FANCD2 and FANCI are not 
interdependent for their nuclear localization per se: in unperturbed conditions, cells 
simply upregulate the nuclear import of residual FANCI in absence of FANCD2 and vice 
versa, possibly in an attempt to partially compensate for one another.  During replication 
stress however, the reduced FANCI and FANCD2 protein levels in I-/- and D2-/- cells, 
respectively, become limiting and block sufficient nuclear FANCD2 and FANCI 
accumulation.  Inconsistent with this interpretation, it has been reported that the FA-D2 
patient cell line, PD20, lacks any nuclear FANCI protein compared to the complemented 
PD20+D2 cells (171).  We suggest that this discrepancy may be because the difference in 
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FANCI protein expression appears to be greater between the PD20 cells and the highly 
FANCD2-overexpressing PD20+D2 cells (145) than between our D2-/- and D2-/-:D2 cells. 
Different roles for chromatin-bound and non-chromatin-bound FANCD2 and 
FANCI? 
Importantly, the independent nuclear accumulation of FANCD2 and FANCI was not 
mirrored by their chromatin binding behavior, since both proteins appeared to be strongly 
interdependent for chromatin recruitment even in unperturbed conditions.  Considering 
that the three knockout cell lines have significantly different growth rates, the chromatin 
binding ability of FANCD2 and FANCI is not indicative of a cell’s proliferation ability.  
This in turn suggests that FANCD2 and FANCI have functions that do not require a 
direct association with chromatin and supports accumulating evidence that FANCD2 and 
FANCI have independent roles, such as the (only FANCI-mediated) stabilization of the 
FA core complex on chromatin or the (only FANCD2-mediated) support of alternative 
non-homologous end joining (A-NHEJ) DNA repair mechanisms (see also 
Supplementary Figure S7) (69,83,150,151,169,174,184).  Our observation that non-
ubiquitinated FANCD2 is present on chromatin in the absence of FANCI is in agreement 
with our previous findings that non-ubiquitinated FANCD2 binds chromatin in FANCI-
depleted Xenopus extracts (69,151) and supports a recent study that showed that 
FANCD2 binds DNA prior to being monoubiquitinated (185).  Moreover, we have shown 
that low levels of non-ubiquitinated FANCD2 accumulate on chromatin in an APH-
inducible manner to promote replication fork restart, regardless of the presence or 
absence of a functional FA core complex (150).  Finally, this current study shows that I-/- 
cells that have residual levels of chromatin-bound, non-ubiquitinated FANCD2 are still 
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capable of partially supporting replication fork restart following APH or HU treatment; 
moreover, simply increasing the chromatin-bound FANCD2 levels via FANCD2 
overexpression completely alleviated the replication restart defects in these cells.  In toto, 
these observations argue strongly that the non-ubiquitinated FANCD2 isoform is 
functional in its chromatin-bound state. 
Importantly, however, the residual FANCD2 chromatin binding in FANCI-deficient cells 
did not alleviate their ICL sensitivity, reinforcing the model of a linear FA ICL repair 
pathway, where the FANCI-dependent FANCD2 monoubiquitination is crucial for 
cellular ICL resistance (145,147,166,186) (Figure 8A).  Thus, these experiments define a 
separation-of-function for FANCD2 monoubiquitination: it is required for ICL repair but 
dispensable for replication fork restart. 
The striking finding that only D2-/- cells — but not I-/- or ID2 DKO cells — were 
sensitive to HU or APH and exhibited elevated activation of phospho-p53 and p21 
expression is supported by a recent report showing HU sensitivity in FA-D2 patient cells 
(174).  Together, these studies suggest that FANCD2 may prevent FANCI-mediated cell 
death following replication stress (Figure 9).  Since D2-/- cells are indistinguishable from 
I-/- or ID2 DKO cells regarding their spontaneous or stress-induced DNA DSB 
accumulation, and the recruitment of HDR repair factors or the activation of the DDT 
pathway, FANCD2’s role in preventing APH- or HU-triggered cell death appears to be 
separate from its role in protecting chromosomal stability. Moreover, since I-/- and ID2 
DKO cells are equally resistant to HU or APH despite harboring different residual 
chromatin-bound FANCD2 levels, FANCD2’s role in preventing APH/HU-induced cell 
death may in fact not depend on its own chromatin association. Consistent with our 
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findings and interpretation, a role for FANCD2 in preventing apoptosis and cell death 
was also suggested by several groups (187-189).  Moreover, a recent study showed that 
siRNA-mediated knockdown of FANCI, but not FANCD2, substantially reduced cellular 
apoptosis after UV treatment (184).  Clearly, in the future, the mechanistic basis of 
FANCD2’s putative role in cell death induction will be a key question for the field to 
answer (Figure 9). 
Opposing roles for FANCD2 and FANCI during HDR-mediated mechanisms of fork 
recovery and DNA DSB repair?  
In agreement with our previous findings (42,69,70), FANCD2 promoted the restart of 
APH-stalled replication forks, a process that requires several members of the HDR repair 
machinery, including RAD51 (42,69,150,163,190).  The fact that the HDR repair defect 
in D2-/- cells could be almost completely rescued by stabilizing RAD51 filaments via RS-
1 supports a model in which FANCD2 functions to (i) promote replication fork restart 
and (ii) protect nascent DNA from nucleolytic degradation (42,68-70) by promoting 
RAD51 filament formation.  In support of this model, a recent study showed that the 
FANCD2:FANCI heterodimer stabilizes RAD51 filament formation in vitro (182).  It 
should be noted that wild type-like RAD51 foci formation was observed in all three 
knockout cell lines including the D2-/- cells (Figure 5G), seemingly contradicting the idea 
that FANCD2 is required for RAD51 filament formation.  However, findings from our 
laboratory and others (42,190) indicate that foci formation of HDR repair factors, such as 
RAD51 or CtIP, does not occur at intact stalled replication forks, but instead occurs much 
later once the forks have collapsed.  The question, therefore, of whether RAD51 foci can 
form in the absence of FANCD2 remains controversial (182,191-195). 
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I-/- cells exhibited milder defects in HDR-mediated replication restart and DSB repair 
than the D2-/- cells, initially suggesting separate roles for FANCD2 and FANCI during 
HDR as well.  However, two additional findings suggest otherwise: First, overexpression 
of FANCD2 completely rescued HDR-mediated replication restart defects in I-/- cells.  
Second, ID2 DKO cells exhibited a less pronounced HDR defect than the D2-/- cells.  
Thus, FANCI’s role in HDR may be to simply stabilize FANCD2, which by itself is the 
actual recruiter of HDR factors.  In this scenario, the residual chromatin-bound, non-
ubiquitinated FANCD2 would allow I-/- cells to partially support HDR-mediated fork 
restart, similar to chromatin-bound FANCD2 in FA core complex-deficient cells (150).  
Importantly, FANCD2- and FANCI-deficient cells can compensate for their replication 
restart defects by the enhanced firing of new replication origins (69,163), which likely 
counteracts chromosomal instability in the presence of replication stress.  Our finding 
that cells lacking FANCI modestly upregulate new origin firing during replication stress 
seemingly contradicts a recent study showing that FANCI is required for new origin 
firing during replication stress (83).  However, these authors investigated the role of 
FANCI mostly under continuous low replication stress conditions (0.2 mM HU), whereas 
our study used transient, high replication stress conditions (30 µM APH for 6 hr), 
indicating, at the very least, that FANCI is not required for new origin firing when 
replication forks are stalled for several hours. 
Perhaps the most unexpected finding was that cells lacking both FANCD2 and FANCI 
exhibited intermediate HDR repair and replication fork restart defects, more severe than 
FANCI-deficient cells, but less severe than FANCD2-deficient cells.  We suggest at least 
two possible explanations: (A) FANCI actively opposes FANCD2 to negatively regulate 
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HDR or (B) FANCD2 and FANCI work in concert during HDR, but FANCI becomes 
inhibitory to HDR in the absence of FANCD2 (Figure 9).  FANCD2 and FANCI can 
form a protein complex with RAD51 and contribute to RAD51 recruitment to DNA 
(182).  If FANCI is in fact the direct interactor with RAD51 in vivo, the nuclear (but not 
chromatin-bound) FANCI may actively sequester RAD51 away from the DNA in 
FANCD2-deficient cells, causing the particularly severe HDR phenotype observed in 
these cells.  Importantly, in both of these scenarios it would be predicted that the 
overexpression of FANCI would be deleterious for HDR (and presumably, therefore, cell 
viability), which was indeed observed by us and others in our inability to establish 
FANCI-overexpressing complemented clones.  Lastly, it may also be possible that only in 
the absence of both proteins is a compensatory/back-up pathway engaged that can 
facilitate RAD51 recruitment. 
In summary, our findings suggest a model in which FANCD2 and FANCI have partially 
non-overlapping roles in promoting cell survival and HR-mediated fork recovery in the 
presence of APH or HU-induced replication stress. 
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FIGURE LEGENDS 
Figure 1.  rAAV-mediated generation of FANCD2-/- (D2-/-), FANCI-/- (I-/-) and 
FANCI-/-:FANCD2-/- (ID2 DKO) cell lines.  
(A) Schematic of FANCD2 (left panel) and FANCI (right panel) targeting strategies in 
HCT116 cells.  FANCD2 exon 12 and FANCI exon 10 were targeted for deletion by 
rAAV gene targeting.  The first allele targeting was performed using conditional rAAV 
vectors for FANCD2 and FANCI.  The conditional vectors contain rAAV inverted 
terminal repeats (ITRs) (grey boxes), homology arms (white boxes), a NEO selection 
cassette (green boxes) and the targeted exon (blue boxes) flanked by LoxP sites (orange 
triangles).  Targeted clones were treated with Cre recombinase to remove the NEO 
selection cassette.  (B) The second allele targeting was performed in the FANCD2flox/+ 
cell line (f/+) using a FANCD2 knockout rAAV vector and in the FANCIflox/+ cell line 
(f/+) with the same FANCI conditional rAAV vector utilized in the first round of 
targeting.  Targeted clones were treated with Cre recombinase to remove both the NEO 
selection cassette and the conditionally floxed exons, resulting in the generation of 
FANCD2-/- (D2-/-) and FANCI-/- (I-/-) cell lines. 
Figure 2.  Confirmation of D2-/-, I-/- and ID2 DKO cell lines.  
(A) PCR genotyping of D2-/- and I-/- cells and targeting intermediates.  Left panel: 
analyses of DNA fragments for WT (lane 1), D2flox/Neo (lanes 2 and 3), and D2-/- (lanes 4 
and 5) after PCR amplification with primers FANCD2_EX11SF and FANCD2_LoxPSR 
flanking the targeted exon.  Right panel: analyses of DNA fragments after PCR 
amplification from WT (lane 1), Iflox/+ (lane 2), and I-/- (lanes 3 and 4) cells using primers 
FancIc_GG_LIF and FancIcond_GG_LoxR flanking the targeted exon.  The PCR 
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amplification spanning the targeted exons (exon 12 in FANCD2; exon 10 in FANCI) was 
used to confirm the removal of the respective exon in the D2-/- and I-/- cell lines.  M: 1 kb 
markers.  (B) Schematic of the FANCD2 targeting strategy in I-/- cells.  CRISPR/Cas9-
mediated gene targeting was used to functionally inactivate FANCD2 in the I-/- cell line.  
A guide RNA (purple sequence) was designed targeting FANCD2 exon 11 with the Cas9 
cut site (red arrow) overlapping an endogenous BpuEI restriction enzyme recognition site 
(black bar).  The PAM sequence of the sgRNA is shown in blue.  Indels introduced at the 
Cas9 cut site should disrupt the BpuEI cleavage site.  (C) Genotyping of ID2 DKO cells.  
PCR amplification and BpuEI restriction enzyme digestion of FANCD2 exon 11 in WT, 
I-/- and two ID2-/- clones (1 and 2).  Analyses of DNA fragments after PCR amplification 
with primers FancD2_CC_ F2 and FancD2_CC_ R2 (blue arrows from panel B) from 
WT (lanes 1 and 2), I-/- (lanes 3 and 4), and ID2 DKO cells (lanes 5, 6, 7 and 8) that had 
been untreated (lanes 1, 3, 5 and 7) or treated with BpuEI (lanes 2, 4, 6, and 8).  Cleavage 
by BpuEI produces 2 faster migrating fragments (D, lanes 2 and 4).  Resistance (R) to 
BpuEI digestion is seen in lanes 6 and 8 with the two ID2 DKO clones.  (D) Sequence 
confirmation of CRISPR/Cas9 induced bi-allelic frameshift mutations in FANCD2 in the 
two ID2 DKO clones #1 and #2. 
Figure 3.  Initial characterization of the I-/-, I-/-:I, D2-/-, D2-/-:D2 and ID2 DKO cell 
lines. 
FANCD2 and FANCI are completely interdependent for their replication stress-triggered 
monoubiquitination.  (A) WCE was prepared from WT cells (lanes 1 and 2), D2-/- cells 
(lanes 3 and 4) or D2-/-:D2 cells (lanes 5 and 6) that had been untreated (lanes 1, 3 and 5) 
or treated with 2 mM HU for 20 hr (lanes 2, 4 and 6) and analyzed for the presence of 
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FANCD2 and FANCI by western blot analysis.  Ku86 was used as a loading control.  (B) 
WCE were prepared from WT cells (lanes 1 and 2), I-/- cells (lanes 3 and 4), I-/-:I (clone 7) 
cells (lanes 5 and 6), I-/-:I (clone 11) cells (lanes 7 and 8), and ID2 DKO cells (lanes 9 and 
10) that were untreated (lanes 1, 3, 5, 7 and 9) or treated with 2 mM HU for 20 hr (lanes 
2, 4, 6, 8 and 10) and analyzed for the presence of FANCD2 and FANCI by western blot 
analysis.  Ku86 was used as a loading control.  (C) FANCD2 and FANCI are partially 
stable in the absence of one another.  Left panel: WCE were prepared from WT (lanes 1, 
4 and 7), D2-/- (lanes 2, 5 and 8), and I-/- (lanes 3, 6 and 9) cells that were untreated (lanes 
1 to 3) or treated with 2 mM HU for 6 hr (lanes 4 to 6) or for 20 hr (lanes 7 to 9) and 
analyzed for FANCD2 and FANCI expression by western blot analysis.  Tubulin was 
used as a loading control.  Right panel: Immunoblot signals shown in the left panel were 
analyzed by densitometry and normalized against the tubulin signals using ImageJ 
software.  The graph shows the percentage of FANCD2 and FANCI protein levels in I-/- 
and D2-/- cells, respectively, compared to the WT cells.  (D) Nuclear import of FANCD2 
and FANCI becomes interdependent during replication stress.  Nuclear fractions were 
isolated from WT, D2-/- and I-/- cells that were untreated (lanes 1 to 3) or HU-treated 
(lanes 4 to 9) for the indicated time points and analyzed for the presence of FANCD2 and 
FANCI.  Ku86 was used as a loading control.  (E) Non-ubiquitinated FANCD2 binds 
chromatin independently of FANCI during normal replication and following replication 
stress.  Chromatin fractions were isolated from WT, D2-/- and I-/- cells that were untreated 
(lanes 1 to 3) or HU-treated (lanes 4 to 9) for the indicated time points and analyzed for 
the presence of FANCD2 and FANCI.  Ku86 was used as a loading control. 
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Figure 4.  FANCD2 and FANCI contribute differently to cell proliferation and the 
cellular response to replication stress. 
(A) The absence of FANCD2 and FANCI affects cell proliferation synergistically. WT, 
D2-/-(clones #29 and #39), I-/- (clones #28 and #30) and ID2 DKO (clones #1 to #4) cells, 
as well as the complemented counterparts, were plated according to their plating 
efficiency and total cell counts were performed in triplicate at days 4, 6 and 8.  Data 
points were averaged between clones of identical genetic backgrounds.  Error bars 
represent the standard deviation.  (B) FANCD2 and FANCI act in concert to promote 
MMC resistance.  Cell viability was measured for WT, D2-/-, I-/-, ID2 DKO and 
complemented cell lines using CellTiter96 Aqueous staining 5 days after the addition of 
0, 5, 10 or 15 nM MMC.  Results were averaged from a minimum of 3 replicates and 
normalized to the average viability of the respective untreated cells.  Error bars represent 
the standard deviation.  (C) FANCD2 and FANCI act in concert to activate the MMC-
triggered intra-S phase checkpoint.  WT, D2-/-(clones #29 and #39), I-/- (clones #28 and 
#30) and ID2 DKO (clones #1 and #2) cells, as well as the complemented counterparts, 
were untreated or treated with 10 nM MMC for 20 hr, followed by propidium iodide (PI) 
staining and FACS analysis.  Representative histograms of the cell cycle profiles are 
shown for each cell line.  Blue shading represents G1 phase cells, orange shading 
represents S phase cells and grey shading represents G2/M phase cells.  (D) Graphic 
representation of the percentage of the indicated cell populations present in the G2/M 
phase of the cell cycle in the absence or presence of MMC.   Data points were averaged 
between clones of identical genetic backgrounds.  The average percentage of the G2/M 
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cell population was determined from a minimum of 3 replicates.  Error bars represent the 
standard deviation and the significance was determined by t-test. 
Figure 5.  FANCI promotes replication stress-induced cellular apoptosis in the 
absence of FANCD2. 
(A) FANCD2, but not FANCI, promotes cellular resistance to HU.  WT, D2-/-(clone #39), 
I-/- (clone #28) and ID2 DKO (clone #1) cells, as well as the complemented cell lines 
were plated at low density and incubated with increasing doses of HU (0 to 150 µM) for 
12 to 14 days to allow for single cell colony formation.  Plates were fixed and stained 
with Coomassie, and colonies with a minimum of 50 cells were scored.  Results were 
averaged from a minimum of 3 replicates and normalized to the respective untreated 
cells.  Error bars represent the standard deviation and significance was determined by t-
test.  Statistical significance at p < 0.05, p < 0.01, and p < 0.001 are indicated as *, **, 
***, respectively.  (B) FANCD2, but not FANCI, promotes cellular resistance to APH.  
WT, D2-/-(clone #39), I-/- (clone #28) and ID2 DKO (clone #1) cells, as well as the 
complemented cell lines were plated at low density and incubated with increasing doses 
of APH (0 to 50 nM) for 12 to 14 days to allow for single cell colony formation.  Plates 
were fixed and stained with Coomassie, and colonies with a minimum of 50 cells were 
scored.  Results were averaged from a minimum of 3 replicates and normalized to the 
respective untreated cells.  Error bars represent the standard deviation and significance 
was determined by t-test.  Statistical significance at p < 0.05, p < 0.01, and p < 0.001 are 
indicated as *, **, ***, respectively.  (C) FANCD2 and FANCI are dispensable for the 
prevention of spontaneous or replication stress-induced DNA DSBs.  WCE were 
prepared from WT (lanes 1 and 5), D2-/- (lanes 2 and 6), I-/- (lanes 3 and 7), and ID2 DKO 
63	  
	  
(lanes 4 and 8) cells that were untreated (lanes 1 to 4) or treated with 500 µM HU for 20 
hr (lanes 5 to 8) and analyzed for the induction of pRPA32 (S4/8) and γ-H2AX 
expression by western blot analysis.  GAPDH was used as a loading control.  (D) WCE 
was prepared from WT (lanes 1 and 5), D2-/- (lanes 2 and 6), I-/- (lanes 3 and 7), and ID2 
DKO (lanes 4 and 8) cells that were untreated (lanes 1 to 4) or treated with 2 mM HU for 
20 hr (lanes 5 to 8) and analyzed for DNA DSB markers, pRPA32 (S4/8) and γ-H2AX by 
western blot analysis.  GAPDH was used as a loading control.  (E) FANCD2 and FANCI 
cooperate to recruit CtIP to chromatin in the absence or presence of replication stress.  
Chromatin fractions were isolated from WT, D2-/- (clone #39) and I-/- (clone #28) cells 
that were untreated (lanes 1 to 3) or treated with 2 mM HU (lanes 4 to 9) for the indicated 
time points and analyzed for the presence of CtIP by western blot analysis.  Ku86 was 
used as a loading control.   (F) FANCD2 and FANCI cooperate to promote CtIP foci 
formation during replication stress.  WT, D2-/- (clone #39), I-/- (clone #28)  and ID2 DKO 
(clone #1) cells were untreated or treated with 2 mM HU for 20 hr and cellular nuclei 
were analyzed for the presence of CtIP foci.  Nuclei with >5 foci were considered 
positive for CtIP foci formation.  (G) FANCD2 and FANCI are dispensable for RAD51 
foci formation during replication stress.  WT, D2-/- (clone #39) and I-/- (clone #28) and 
ID2 DKO (clone #1) cells were untreated or treated with 2 mM HU for 20 hr and cellular 
nuclei were analyzed for the presence of RAD51 foci.  Nuclei with >5 foci were 
considered positive for RAD51 foci formation. (H)  FANCD2 and FANCI cooperate to 
promote the monoubiquitination of chromatin-bound PCNA in the absence or presence of 
HU-triggered replication stress.  Chromatin fractions were isolated from WT, D2-/- (clone 
#39), I-/- (clone #28) and ID2 DKO (clone #1) cells that were untreated (lanes 1, 3, 5, and 
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7) or treated with 2 mM HU (lanes 2, 4, 6, and 8) for 20 hr and analyzed for the presence 
of PCNA and PCNAUb by western blot analysis.  H2AX was used as a loading control. (I) 
FANCD2 prevents FANCI-dependent cellular apoptosis in unperturbed conditions and 
following replication stress.  WCE were prepared from WT (lanes 1 and 5), D2-/- (lanes 2 
and 6), I-/- (lanes 3 and 7), and ID2 DKO (lanes 4 and 8) cells that were untreated (lanes 1 
to 4) or treated with 100 nM APH for 20 hr (lanes 5 to 8) and analyzed for phospho-p53 
(S15) and p21 by western blot analysis.  Ku86 was used as a loading control. 
Figure 6.  FANCD2 plays a more crucial role than FANCI to promote replication 
fork recovery.  
(A) Schematic of the replication fork restart protocol with representative images of DNA 
fibers.  Red tracks: DigU; green tracks: BioU.  (B) FANCD2 plays a more crucial role 
than FANCI in promoting the restart of APH-stalled replication forks.  The efficiency of 
replication restart in WT, D2-/- (clone #39), I-/- (clone #28) , and ID2 DKO (clone #1), as 
well as in the complemented cells was measured as the number of restarted replication 
forks after APH (30 µM) mediated fork stalling (DigU-BioU tracts), compared with the 
total number of DigU-labeled tracts (DigU plus DigU-BioU).  Statistical significance at p 
< 0.05, p < 0.01, and p < 0.001 are indicated as *, **, ***, respectively.  (C) FANCD2 
plays a more crucial role than FANCI in suppressing new origin firing in the presence of 
stalled replication forks.  WT, D2-/- (clone #39), I-/- (clone #28) , and ID2 DKO (clone #1), 
as well as the complemented cells were analyzed for the fraction of newly fired 
replication origins during the 40 min post-APH recovery period.  Fractions were 
measured as the number of green-only (BioU) tracts compared with the total number of 
spreading replication tracts (BioU plus DigU-BioU).  Statistical significance at p < 0.05, 
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p < 0.01, and p < 0.001 are indicated as *, **, ***, respectively.  (D) Schematic of the 
DNA combing assay with representative images of stretched DNA fibers.  Green tracks: 
CldU; red tracks: IdU.  (E) FANCD2 plays a more crucial role than FANCI in promoting 
the restart of HU-stalled replication forks.  The efficiency of replication restart in WT, 
D2-/-(clones #29 and #39), I-/- (clones #28 and #30) and ID2 DKO (clones #1 and #2) was 
measured as the number of restarted replication forks after HU-mediated fork stalling 
(CldU-IdU tracts), compared with the total number of CldU-labeled tracts (CldU plus 
CldU-IdU).  Data points were averaged between clones of identical genetic backgrounds. 
Statistical significance at p < 0.05, p < 0.01, and p < 0.001 are indicated as *, **, ***, 
respectively.   
Figure 7.  Over-expressed FANCD2 fully promotes replication fork restart in the 
absence of FANCI 
(A) Human wild type FANCD2 can be stably overexpressed in I-/- cells. A PiggyBac 
transposon containing the FANCD2 codon-optimized cDNA was introduced into I-/- cells 
(clone #28), and two FANCD2-overexpressing I-/- cell lines (named I-/-:D2o/e, clones #2 
and #12) were generated. To determine the level of FANCD2 overexpression, WCEs 
were prepared from WT (lanes 1 and 2), I-/- (lanes 3 and 4), and I-/-:D2o/e (lanes 5 to 8) 
cells that were untreated (lanes 1, 3, 5, 7) or treated with 4 mM HU for 4 hr (lanes 2, 4, 6, 
and 8) and analyzed for the presence of FANCD2 by western blot analysis.  Actin was 
used as a loading control. (B) Overexpression of FANCD2 leads to an increase in 
FANCD2 chromatin binding in the absence of FANCI. In parallel to the preparation of 
WCEs described in (A) above, chromatin fractions were isolated from these same WT 
(lanes 1 and 2), I-/- (lanes 3 and 4), and I-/-:D2o/e (lanes 5 to 8) cells that were untreated 
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(lanes 1, 3, 5, 7) or treated with 4 mM HU for 4 hr (lanes 2, 4, 6, and 8) and analyzed for 
the presence of FANCD2 by western blot analysis. H3 was used as a loading control. (C) 
FANCD2 overexpression rescues the replication fork restart defects in FANCI null cells. 
The efficiency of replication fork restart in WT, D2-/-, I-/-, and I-/-:D2o/e cells was measured 
as the number of restarted replication forks after HU-mediated fork stalling (CldU-IdU 
tracts), compared with the total number of CldU-labeled tracts (CldU plus CldU-IdU). 
Statistical significance at P<0.05, P<0.01, and P<0.001 are indicated as *, **, ***, 
respectively. 
Figure 8.  FANCD2 plays a crucial role to promote HDR-mediated, RAD51-
dependent DNA DSB repair. 
(A) A GFP-HDR DNA repair assay was used to determine the HDR efficiency in WT, 
D2-/-(clones #29 and #39), I-/- (clones #28 and #30) and ID2 DKO (clones #1 and #2), as 
well as in the complemented cells.  RAD54B-/-/- cells were included in the assay as a 
control cell line that is severely HDR deficient. In this assay, I-SceI restriction enzyme 
digestion creates a DSB in the HDR reporter plasmid (DR-GFP).  Repair of the DSB by 
HDR restores GFP expression.  The repair efficiency was determined by dual GFP and 
mCherry positive cells divided by the mCherry positive cells (transfection control).  
Results were averaged from a minimum of 3 replicates and normalized to the average 
repair efficiency in the WT cells.  Data points were averaged between clones of identical 
genetic backgrounds.  Statistical significance at p < 0.05, p < 0.01, p < 0.001 and p < 
0.0001 are indicated as *, **, ***, **** respectively.  (B) The HDR assay shown in (A) 
was repeated for the WT, D2-/-, I-/- and ID2 DKO cells in the absence or presence of the 
RAD51 stabilizer, RS-1 (7.5 mM).  Results were averaged from a minimum of 3 
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replicates and normalized to the average repair efficiency in the WT cells.  Statistical 
significance at p < 0.05, p < 0.01, p < 0.001 and p < 0.0001 are indicated as *, **, ***, 
**** respectively. 
Figure 9.  Model of common and independent functions of FANCD2 and FANCI 
(A)FANCD2 and FANCI act in concert during the cellular response to DNA ICLs in S-
phase to promote ICL removal and cell survival.  (B and C) FANCD2 and FANCI have 
separate roles during the cellular response to APH- or HU- stalled replication forks.  (B) 
FANCD2 – but not FANCI – is crucial to recruit RAD51 and promotes RAD51 filament 
formation to mediate fork recovery.  (C) Simultaneously, FANCD2 promotes cell 
survival by inhibiting a FANCI-dependent lethal response. 
Supplementary Figure S1.  CRISPR/Cas9-mediated gene targeting to create 
additional D2-/-  clone 29 and DKO clones 3 and 4 
(A) Schematic of the CRISPR/Cas9-mediated gene targeting to knockout FANCD2 in 
WT cells to create D2-/- clone #29.  A guide RNA was designed targeting FANCD2 exon 
11 with the Cas9 cut site overlapping with an endogenous BpuEI restriction enzyme 
recognition site.  Indels introduced at the Cas9 cut site (red arrow) would disrupt the 
BpuEI cut site.  Sequence confirmation of biallelic frameshift inducing mutations.  (B) 
Schematic of the CRISPR/Cas9-mediated gene targeting to knockout FANCI in D2-/- 
clone #29 cells to create ID2-/- clone 3.  A guide RNA was designed targeting FANCI 
exon 9 with the Cas9 cut site overlapping with an endogenous AcuI restriction enzyme 
recognition site.  Indels introduced at the Cas9 cut site (red arrow) would disrupt the AcuI 
recognition sequence.  Bottom: Sequence confirmation of biallelic frameshift-inducing 
mutations.  (C) Schematic of the CRISPR/Cas9-mediated gene targeting to knockout 
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FANCI in D2-/- clone #39 cells to create the ID2-/- DKO clone #4.  A guide RNA was 
designed targeting FANCI exon 9 with the Cas9 cut site overlapping with an endogenous 
AcuI restriction enzyme recognition site.  Indels introduced at the Cas9 cut site (red 
arrow) would disrupt the AcuI recognition sequence.  Sequence confirmation of biallelic 
frameshift inducing mutations.  (D-E) No truncated FANCD2 or FANCI proteins are 
observed in the null cell lines.  (D) WCE from WT, D2-/-, and ID2-/- were analyzed for the 
presence of FANCD2 (Santa Cruz; sc-20022, 1:1000).  Tubulin was used as a loading 
control.  (E) WCE from WT, I-/-, and ID2-/- were analyzed for the presence of FANCI 
(Bethyl; A300-212, 1: 1000). 
Supplementary Figure S2.   D2-/-, I-/- and ID2-/- G2/M arrest in response to MMC  
Percentage of cells in each phase of the cell cycle to accompany Figure 4C.  WT, D2-/-, I-
/-, ID2-/- and complemented cell lines were untreated or treated with 10 nM MMC 24 hr, 
followed by propidium iodine (PI) staining and FACS analysis to determine the 
percentage of cells in each phase of the cell cycle, in triplicate.  The average from two 
independent clones for D2-/-, I-/- and ID2-/- cells is reported. 
Supplementary Figure S3. FANCD2, but not FANCI, promotes cellular resistance to 
APH and HU in additional independent clones for D2-/-, I-/- and ID2-/- to accompany 
Figure 5. 
FANCD2, but not FANCI, promotes cellular resistance to APH and HU in additional 
independent clones for D2-/-, I-/- and ID2-/- to accompany Figure 5.  WT, D2-/-, I-/-, and 
ID2-/- cell lines were plated at low density and incubated in absence or presence of HU 
(50, 100 and 150 µM) or APH (10, 25 or 50 nM) for 12 to 14 days to allow for single cell 
colony formation.  Plates were fixed and stained with Coomassie, and colonies with a 
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minimum of 50 cells were scored.  Results were averaged from a minimum of 3 replicate 
wells for each cell line and normalized to the respective untreated cells.  Error bars 
represent the standard deviation and significance was determined by t-test. Statistical 
significance at P<0.05, P<0.01, and P<0.001 are indicated as *, **, ***, respectively, 
and is in comparison to normalized WT survival under the same conditions. 
Supplementary Figure S4. CtIP foci images 
 
Defective induction of CtIP in D2-/-, I-/- and ID2-/- cell lines.  Cells from the indicated cell 
lines were either left untreated or treated with 4 mM HU for 20 hr.  The cell nuclei (blue) 
were then identified by staining with DAPI.  The cells were also stained (green) with an 
antibody that detects CtIP followed by incubation of the cells with a fluorescent 
secondary antibody.   For statistical analysis of nuclear foci formation, images were taken 
using a Leica DM LB2 microscope with a Hamamatsu Orca-ER camera.  Quantification 
of CtIP foci was carried out using ImageJ. 
Supplementary Figure S5. RAD51 foci images 
Normal induction of RAD51 foci in D2-/-, I-/- and ID2-/- cell lines.  Cells from the 
indicated cell lines were either left untreated or treated with 4 mM HU for 20 hr.  The cell 
nuclei (blue) were then identified by staining with DAPI.  The cells were also stained 
(green) with an antibody that detects RAD51 followed by incubation of the cells with a 
fluorescent secondary antibody.   For statistical analysis of nuclear foci formation, images 
were taken using a Leica DM LB2 microscope with a Hamamatsu Orca-ER camera.  
Quantification of RAD51 foci was carried out using ImageJ. 
Supplementary Figure S6.  FANCD2 is dispensable for replication stress-induced 
RAD51 foci formation in a human fibroblast cell line. 
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An FA-D2 patient-derived cell line (PD20) and its complemented counterpart 
(PD20+D2) were left untreated or treated with 2 mM HU for 20 hr.  Cellular nuclei were 
analyzed for the presence of RAD51 foci.  Nuclei with >5 foci were considered positive 
for RAD51 foci formation. 
Supplementary Figure S7. FANCD2 and FANCI both have a role in maintaining 
normal cell cycle response to APH 
FANCD2 and FANCI both have a role in maintaining normal cell cycle response to APH.  
WT, D2-/-, I-/-, ID2-/- and complemented cell lines were untreated or treated with 100 nM 
APH for 24 hr, followed by propidium iodine (PI) staining and FACS analysis to 
determine percentage of cells in each phase of the cell cycle, in triplicate.   (A) 
Representative histograms of the cell cycle profile are shown for each cell line.  Blue 
shading represents G1 phase cells, orange shading represents S phase cells and grey 
shading represents G2/M phase cells.  (B) Percentage of cells in each phase of the cell 
cycle.  The average from two independent clones for D2-/-, I-/- and ID2-/- cells is reported. 
Supplementary Figure S8. FANCD2, but not FANCI, functions to promote ANHEJ-
mediated DNA DSB repair 
FANCD2, but not FANCI, functions to promote A-NHEJ-mediated DNA DSB repair.  
WT, D2-/-, D2-/-+D2, I-/-, I-/-+I, and ID2-/- cells were used.  In this assay, I-Scel digestion 
creates a DSB in the A-NHEJ reporter plasmid (EJ2-GFP).  Repair of the DSB by 
microhomology-mediated repair restores GFP expression.  The repair percentage was 
determined by the number of dual GFP and mCherry positive cells divided by the number 
of mCherry positive cells (transfection control).  Results were averaged from a minimum 
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of 3 replicates.  Error bars represent the standard deviation and significance was 
determined by t-test. Statistical significance at P < 0.05, P < 0.01, P < 0.001, P < 0.0001 
are indicated as *, **, ***, **** respectively. 
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Data generated in Figure 3 by Jung Eun Yeo 
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Data generated in Figure 5 A, B by Elizabeth Thompson and C, D by Jung Eun Yeo 
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Data generated in Figure 5 E-I by Jung Eun Yeo 
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Data generated in Figure 6 by Jung Eun Yeo 
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Data generated in Figure 7 by Jung Eun Yeo 
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Data generated in Supplementary Figure S4 by Jung Eun Yeo 
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Data generated in Supplementary Figure S5 by Jung Eun Yeo 
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Data generated in Supplementary Figure S6 by Jung Eun Yeo 
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Data generated in Supplementary Table S2 by Elizabeth Thompson and Jung Eun Yeo 
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CHAPTER 3 
 
PALB2 IS AN ESSENTIAL GENE AND PROTECTS THE 
GENOME FROM CATASTROPHIC INSTABILITY 
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SUMMARY 
Partner and localizer of BRCA2 (PALB2) is an important tumor suppressor that is 
associated with Fanconi anemia (FA) and breast cancer susceptibility.  Indeed, FA 
patients with mutations in PALB2 (the FA-N subtype; FANCN) typically have more 
severe disease with earlier onset of cancer.  PALB2 is known to promote homology 
dependent recombination (HDR) by complexing with both breast cancer allele 1 and 2 
(BRCA1 and BRCA2) and facilitating radiation sensitive 51 (RAD51) strand invasion.  
To further investigate the function of PABL2, we used recombinant adeno-associated 
virus (rAAV)-mediated gene targeting techniques to make a conditionally null human 
PALB2 cell line.  Removal of the conditional allele resulted in spontaneous chromosomal 
breaks and rearrangements that ultimately lead to chromosomal catastrophe within two 
cell cycles.  Successful complementation of the PALB2-null cell line was accomplished 
using cDNAs encoding three FA-associated truncating mutations and three PALB2 single 
nucleotide polymorphisms (SNPs) identified in breast cancer patients.  These 
experiments demonstrated that the PALB2 patient mutations were hypomorphic because 
they could rescue the viability of the PALB2 null cell line and that PALB2’s essential role 
in genomic stability is replication dependent.  Furthermore, we confirmed that the 
PALB2 mutants (all of which did not express the C-terminal WD40 domain) could still 
bind BRCA2, but were defective in RAD51 foci formation and were HDR deficient. 
These experiments identified several novel important separation-of-function 
characteristics: PALB2’s essential activity is separable from its ability to interact with 
BRCA2 and with its HDR activity.  Similarly, the analysis of the SNP mutants proved 
informative.  All of the SNP mutants were capable of forming a complex with RAD51.  
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Importantly, however, two of the three SNP mutants were as sensitive to mitomycin C 
(MMC), poly(ADP-ribose) polymerase 1 (PARP1) inhibitors and replication stress as the 
pathogenic FA mutations.  Thus, we identified two cancer-associated PALB2 SNPs that 
are sensitive to interstrand crosslinks and defective in DNA repair and are thus 
potentially pathogenic mutations.  In conclusion, this research has revealed a mechanistic 
understanding of PALB2 function and how PALB2 patient mutations result in disease. 
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INTRODUCTION 
PALB2/FANCN is an important tumor suppressor and DNA repair protein with roles in 
repairing two of the most toxic DNA lesions, ICL (interstrand cross links) and DSB 
(double strand breaks) (129,130) that can occur in human cells.  PALB2 was first 
described as a binding partner for BRCA2 (134), but has since been recognized as a 
molecular scaffold coordinating HDR with BRCA1, BRCA2, RAD51 and RAD51C 
(129,130,196).  As a well-established tumor suppressor, biallelic mutations of PALB2 are 
associated with the chromosomal instability disorder FA (138,197) and monoallelic 
mutations are associated with predisposition to hereditary breast, ovarian, prostate and 
pancreatic cancer (198-205).  Thus, a mechanistic understanding of PALB2 function(s) 
and how patient mutations lead to disease should provide valuable insight into cancer 
etiology and prevention. 
The characterization of the structural and protein binding domains of PALB2 have 
helped define PALB2 as a “molecular scaffold” in coordinating HDR and DSB repair 
(129,130,206).  The N-terminus contains a coiled-coil domain that is the site of BRCA1 
interaction and has been identified as the PALB2 homo-oligomerization domain as well 
(207,208).  The N-terminus also contains binding domains for DNA, RAD51, and Kelch-
like ECH-associated protein 1 (KEAP1).  KEAP1 is an E3 ubiquitin ligase that has been 
implicated in the detection and cellular response to oxidative stress (209,210).  In 
addition, KEAP1 can ubiquitinate N-terminal PABL2 lysines that prevent BRCA1 
binding to PALB2 in a cell cycle dependent manner, and this ubiquitination can suppress 
HDR in G1 phase of the cell cycle (211).  The central region of PALB2 contains a 
chromatin associated motif (ChAM), a second DNA binding domain, and a binding site 
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for MORF-related gene on chromosome 15 (MRG15), which is a transcription factor and 
part of a chromatin modifying complex.  The ChAM domain and MRG15 work together 
to localize PALB2 to chromatin and promote HDR (212-214).  The C-terminus of 
PALB2 contains a tryptophan-aspartic acid 40 (WD40) domain that mediates interaction 
with proteins involved in HDR and replication stress including BRCA2, RAD51, 
RAD51C, X-ray cross-complementing 3 (XRCC3) and DNA polymerase eta (pol η) 
(196,215).  This WD40 domain forms a protein:protein binding structure called a 7-
bladed beta-propeller (128,216) that is especially important for the localization of 
BRCA2 and RAD51 (131,132,196,217,218). 
 FA patients with the FA-N subtype typically have a severe clinical phenotype, 
similar to the BRCA2 subtype FA patients, with an early onset of cancer, including 
embryoid tumors such as Wilm’s tumor, medulloblastoma and neuroblastoma 
(138,219,220).  Interestingly — from a molecular genetics’ perspective — most of the 
pathogenic PALB2/FANCN mutations are truncating mutations resulting in the loss of 
the C-terminus and WD40 domain where BRCA2 binds (130,138,197).  The importance 
of the PALB2’s C-terminus is additionally reinforced by the observation that 
heterozygous inheritance of a C-terminal truncating mutation in PALB2 can result in a 
six-fold increase in the incidence of breast cancer (136,221,222).  In contrast, and 
somewhat surprisingly, very few missense mutations in PALB2 have either been 
described or characterized (130,223).	  
To address the function of PALB2, and especially to advance our understanding of 
PALB2’s roles in cellular viability and HDR, we set out to a create a conditionally-null 
PALB2 knockout in the human HCT116 cell line.  We choose a conditionally-null 
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approach for two reasons.  First, the attempted creation of a PALB2 knockout mouse 
resulted only in embryonic lethality (224), and second, while several PALB2 patient cell 
lines have been established they all have detectable (albeit mutant) protein expression 
(197,201,225,226), suggesting strongly that the mutations are hypomorphic.  Here, we 
demonstrate that the removal of PALB2 from human cells is lethal and results in a rapid 
and extremely profound chromosome fragmentation phenotype.  In addition, we then 
utilized this cell line in a functional rescue approach to evaluate the function of known 
PALB2 pathogenic patient mutations and SNPs of unknown significance.  Importantly 
we were able to identify mutations that genetically separated the essential activity of 
PALB2 from its activity required for HDR.  Thus, quite unexpectedly, we have 
demonstrated that HDR is likely not the essential activity of PALB2.  Just as importantly 
— from a clinical perspective — we were able to demonstrate that cell lines expressing 
two of the three PALB2 SNPs are sensitive to mitomycin C (MMC), aphidicolin (APH), 
and olaparib and have HDR defects, suggesting they are potentially pathogenic 
mutations.  In toto, these studies significantly advance our mechanistic understanding of 
the role(s) that PALB2 is required for in human somatic cells. 
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MATERIALS AND METHODS 
Generating a PALB2 inducible, conditionally-null  cell line by rAAV-mediated gene 
targeting 
A conditional PALB2 knockout was generated using rAAV-mediated gene targeting 
(Figure 1A).  Two targeting rAAV vectors were made using Golden Gate cloning 
techniques as described (152,153,181).  Based on their proximity and the small size of 
the exons, we selected both exons 2 and 3 for targeting.  In addition, deletion of both 
exons 2 and 3 should result in a frameshift mutation and very premature truncation of any 
possible protein product.  Thus, a conditional vector was designed to introduce a 
neomycin (NEO) selection cassette and loxP sites flanking exons 2 and 3.  This 
conditional rAAV PALB2 vector was transduced into the HCT116 cell line.  G418 
selection and PCR were used to identify correctly targeted subclones (PALB2floxNEO/+).  
Correctly targeted cells were subsequently transduced with a transient Cre recombinase-
expressing adenovirus (AdCre).  The resulting subclones were screened for the loss of the 
NEO selection cassette, but retention of the floxed exons 2 and 3 to create the conditional 
allele (PALB2flox/+).  The second round of targeting was then performed with a knockout 
vector that simply replaced exons 2 and 3 with a NEO selection cassette (PALB2flox/NEO).  
AdCre was used again to remove the NEO selection cassette and subclones were 
screened by PCR to identify cell lines with the correct allelic configuration (PALB2flox/-) 
(Figures 1A & 1B).  The sequences for all primers used in these reactions can be found in 
Supplementary Table S1.   
An inducible gene knockout of PALB2 was created with a Cre recombinase fused to 
the estrogen receptor ligand-binding domain (CreER) system.  A PiggyBac transposon 
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containing the Cre-ER systems and a puromycin resistance gene (PURO) was used to 
isolate clones in which the vector had stably integrated.  Loss of the conditional allele 
could then be obtained at the experimenter’s discretion with the addition of tamoxifen or 
5 nM of 4-hydroxytamoxifen (4-OHT) (227).  The loss of the conditional PALB2 allele 
upon 4-OHT treatment could be confirmed by PCR amplification with allele-specific 
primers flanking the targeted locus (Figure 1B). 
Growth curves 
Wild type (WT) HCT116 cells and two independent clones of the PALB2flox/-:Cre-ER cell 
line (clones 3 and 31) were plated in 6-well plates.  WT cells were subcultured at 3,500 
cells/well.  PALB2flox/-:Cre-ER cells were subcultured at 5,000 cells/well for untreated wells 
and 20,000 cells/well for PALB2flox/-:Cre-ER + 4-OHT wells.  4-OHT (10 nM) [you said 5 
in the paragraph above] was added to one half of the plates.  Cell counts were derived in 
triplicate on the indicated days (3, 5, 7 and 11) from both the 4-OHT-treated and 
untreated wells. 
Cytogenetics 
PALB2flox/-:Cre-ER cells and PALB2-/- + WT cDNA cells untreated or treated with 10 nM 
4-OHT for 24, 48, or 72 hr were subjected to cytogenetic analysis at the University of 
Minnesota’s cytogenomics core laboratory.  Thirty metaphases were analyzed by G-
banding karyotyping for all samples except that only 20 metaphases were scored for 
PALB2flox/- cells treated with tamoxifen at 48 and 72 hr due to their low mitotic index.  
The results are summarized in Supplementary Table S3. 
Replication assay 
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Two independent clones of the PALB2flox/-:Cre-ER cell line were tested in complete media 
(10% fetal bovine serum; FBS) and low serum (1% FBS) to determine if reducing the 
growth rate could also reduce the amount of cell death of PALB2-deficient cells.  Cells 
were subcultured in 6-well plates at 50,000 cells/well for complete media samples and 
150,000 cells/well for low serum samples.  The next day the complete media was 
removed and then complete media or low serum media, either with or without 10 nM 4-
OHT was added to the wells in triplicate.  Cell counts were derived at two and four days 
after tamoxifen treatment.  The change in cell number was determined between day 2 and 
day 4 by subtracting day 4 cell counts from the average cell count on day 2 for each 
condition.  The percent change in cell number was then determined based on the average 
cell count from day 2.  Data was combined from the two independent clones. 
PALB2 mutations 
Fanconi anemia patient mutations 
Mutation c.1653T>A, p.Tyr551* (Y551X) is a nonsense mutation resulting in a 
premature truncation in exon 4 of PALB2.  This truncation results in the loss of the 
WD40 and MRG15 binding domains.  This mutation was the first PALB2 mutation 
associated with an FA patient (197) and the patient was a compound heterozygote who 
had this mutation and c.(?_200)_(3113+1_3114-1)del, a large deletion (presumed to be a 
null allele) encompassing exons 1 to 10 on the other PALB2 allele (228).  The patient’s 
clinical presentation included skin, heart, thumb and kidney abnormalities, growth 
retardation, and anemia.  The patient died at the age of 2 due to a rare and aggressive 
form of endothelia cancer, kapsosiform hemangioendothelioma (197). 
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Mutation c.2257C>T, p.Arg753* (R753X) is a nonsense mutation resulting in a 
premature truncation in PALB2 exon 5.  This truncation results in the loss of the WD40 
domain and the majority of the MRG15 binding domain.  This mutation is a bona fide FA 
and breast cancer associated mutation (130).  The patient was a compound heterozygote 
with this mutation and Y1183X.  The patient’s clinical presentation included a Wilms 
tumor diagnosis at age 1, severe intrauterine growth retardation, growth retardation, 
microcephaly, microphthalmia, and skin hyperpigmentation (138). 
Mutation c.3549C>G, p.Tyr1183* (Y1183X) is a nonsense mutation resulting in a 
premature truncation in PALB2 exon 13.  This 4 amino acid truncation of the C-terminus 
has been implicated as destabilizing to the 7-bladed β-propeller WD40 domain (128).  
This mutation is associated with FA, breast cancer and pancreatic cancer (130) and was 
found in three unrelated FA patients, all compound heterozygous with this mutation and 
R753X, Q988X or N1039fs.  Each of these FA patients had a diagnosis of cancer before 
the age of 3 including the following: Wilms tumor (patient 1), medulloblastoma (patient 
2), and neuroblastoma and acute myelocytic leukemia (AML; patient 3).  Common 
clinical presentation for all 3 patients included growth retardation and microcephaly.  
Two patients also presented with skin hyperpigmentation and two with thumb anomalies 
(138). 
 
Breast cancer variants of unknown significance (VUS) mutations 
A recent study using a next generation sequencing screen of breast cancer-associated 
genes in a population of 2,158 breast cancer patients found PALB2 VUS mutations in 56 
patients (2.6%) (139).  The three VUS missense mutations described below are SNPs that 
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were selected for further analysis because they either occurred in more than one patient 
within this cohort, or because they were associated with high-risk based on family history 
(139). 
Mutations c.298C>T, p.Leu100Phe (L100F) affects the last amino acid in the 
KEAP1 binding domain and is located within a putative DNA binding domain in exon 4.  
This mutation was associated with 3/2158 breast cancer patients. 
Mutation c.656A>G, p.Asp219Gly (D219G) is located in exon 4 between the two 
DNA binding domains, but is otherwise not within any known binding or structural 
domains.  This mutation was associated with 3/2158 breast cancer patients and high-risk. 
Mutation c.1699C>T, p.His567Tyr (H567Y) is located in exon 5 between the ChAM 
domain and the MRG15 binding domain, but not within any known binding or structural 
domains.  This mutation was associated with 1/2158 breast cancer patients and high-risk. 
Structural domain mutation 
A delta coiled-coil mutation (ΔCC).  One structural domain deletion mutant was 
constructed and tested.  The coiled-coil domain (amino acids 9 to 44) was deleted to test 
if the BRCA1 binding and PALB2 homodimerization domains were essential for 
viability. 
Patient mutation complementation 
A PALB2 cDNA was PCR amplified and Gateway cloned into a pDONR 221 plasmid 
and subsequently into a PiggyBac transposon expression vector containing a NEO 
selection cassette and a CAGs promoter.  Site-directed mutagenesis was performed with 
either a QuickChange II Site-Directed Mutagenesis Kit or a Q5 Site-Directed 
Mutagenesis Kit  to incorporate a FLAG epitope tag and the patient mutations.  All 
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primer sequences utilized for these experiments are listed in Supplementary Table S1.  
Flag-tagged WT and patient mutation-containing cDNAs were introduced into the 
PALB2flox/-:CreER cell line by PiggyBac-meidated transposition and G418 selection was 
used to confirm integration.  The remaining floxed PALB2 genomic allele was the 
removed by the addition of 10 nM 4-OHT to the media for 2 days.  Cells were subcloned 
and clones which had lost the endogenous PALB2 allele were identified by PCR 
screening.  One tamoxifen treatment was sufficient to obtain the L100F, D219G, H567Y 
and Y1183X cell lines with the loss of the floxed allele.  However, 3 subsequent 
tamoxifen treatments and cell recovery cycles were necessary to obtain the 
complemented Y551X, R753X and ΔCC cell lines containing the loss of the floxed 
PALB2 allele. 
 
Generating the PALB2 delta C-terminus cell line by CRISPR/Cas9 mediated gene 
targeting 
A gRNA targeting PALB2 exon 5 was designed and incorporated in the CRISPR/Cas9 
plasmid hSpCas9-2A-Puro/px458 as described (Supplementary Figure S1)(229).  A 
single-stranded DNA oligonucleotide (ssODN) was designed to “knock-in” the patient 
mutation R753X along with a novel BseYI restriction enzyme recognition site.  WT 
HCT116 cells were electroporated with 5 ug of the CRISPR/Cas9 plasmid and 1.5 uL of 
100 µM ssODN and allowed to recover for 2 days.  Cells were sorted by fluorescence 
activated cell sorting (FACS) to obtain the green fluorescent protein (GFP; i.e., 
transfected) cell population.  The GFP-positive cells were then subcloned and screened 
by PCR with FancN_Ex5_F1 and FancN_Ex5_R3 primers and a subsequent restriction 
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enzyme digestion with BseYI.  The WT sequence contains one BseYI enzyme 
recognition site in the PCR product and can be digested to two fragments of different 
sizes (342 and 172 bp), whereas a heterozygous knock-in should generate 4 restriction 
enzyme digestion fragments (342, 240, 172 and 92 bp), and a homozygous knock-in 
should produce 3 digestion fragments (250, 172 and 92 bp).  After PCR amplification and 
BseYI restriction enzyme digestion, clones 17 and 67 and 83 indicated that they 
contained possible heterozygous knock-ins and the clones were further analyzed by 
TOPO-TA cloning for allele sequence confirmation.  This analysis showed that two of 
the clones were useful.  Clone 83 contained indeed a heterozygous knock-in of the 
R753X mutation.  Interestingly, Clone 17 contained biallelic mutations consisting of a 
frameshift and C-terminal truncating mutation on one allele (c.2279insT, p.760fs*11) and 
a 65 bp deletion plus a 2 bp insertion resulting in a 21 amino acid in-frame deletion with 
flanking missense mutations on the other allele (c.2268_2332delinsGG, 
p.C757W_S778Gdel) (hereafter referred to as PALB2* cell line).  See Supplementary 
Table S2 for primer, guide and ssODN sequences used in these experiments. 
 
Drug sensitivity testing 
WT and PALB2-/- complemented cells were subcultured in 6-well plates according to 
their plating efficiency.  WT cells were subcultured at 300 cells/well, PALB2-/- 
complemented cells (L100F, D219G, H567Y) were plated at 1,000 to 3,000 cells/well, 
and PALB2-/- complemented cells (Y551X, R753X, Y1183X and ΔCC) were subcultured 
at 5,000 to 8,000 cells/well.  After 24 hr, the old media was removed and new media 
containing 0, 1, 2, 5 nM MMC, 0, 25, 50, 75 nM APH, or 0, 50, 100, 250 nM olaparib 
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was added in triplicate.  Cells were incubated for 12 to 14 days, washed in phosphate 
buffered saline (PBS), fixed in 10% acetic acid/10% methanol and stained with 
Coomassie as described (158).  Colonies reaching a minimum size of 50 cells were 
counted and normalized to the average colony number in untreated wells.  Data is 
averaged from a minimum of 2 independent experiments with a minimum of 3 replicates 
per experiment. 
 
DNA HDR repair assay 
The HDR reporter assay was performed with the DR-GFP plasmid as described (159).  
Briefly, three plasmids including the reporter plasmid (DR-GFP), an I-SceI expression 
plasmid, and a mCherry expression plasmid (which was used as a transfection control) 
were co-transfected into cells using Lipofectamine 3000.  Cells were fixed with 4% 
paraformaldehyde 72 hr after transfection and sorted by FACS.  The number of dual 
GFP-positive and mCherry-positive cells divided by the number of mCherry-positive 
cells was calculated to determine repair efficiencies.  The values were normalized to the 
repair efficiency observed in WT cDNA complemented PALB2-/- cells. 
For the RS-1 treatment used during the HDR assay, 7.5 nM RS-1 was added to the 
media 2 hr prior to plasmid transfection.  Fresh media containing 7.5 nM RS-1 was added 
again 24 hr after transfection.  Normalized repair efficiency with RS-1 was subtracted 
from the normalized repair efficiency without RS-1 and the percent change in efficiency 
from untreated was reported.  Data is averaged from a minimum of 6 replicates from 2 
independent experiments. 
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Immunoblotting 
Untreated WT and PALB2flox/-:CreER cells untreated and treated with 10 nM 4-OHT for 24, 
48, 72, and 96 hr were lysed in radioimmunoprecipitation assay (RIPA) buffer containing 
a Complete Protease Inhibitor cocktail.  Protein concentrations determined and 80 µg of 
each lysate in 1X NuPAGE LDS sample buffer were electrophoresed on a Criterion 4 to 
20% gradient gel and then transferred to Hybond P, polyvinylidene fluoride (PVDF) 
membranes.  Primary antibodies used were a rabbit anti-PALB2 (obtained from B. Xia, 
1:1000) and a mouse anti-Ku86 and secondary goat anti-mouse IgG HRP conjugate or 
donkey anti-rabbit IgG HRP. 
 
Co-immunoprecipitation 
Cells were collected from 75% confluent 10 cm plates with trypsin and washed in PBS.  
All the following steps were performed on ice or at 4oC.  The cells were lysed in 50 mM 
TRIS, 2 mM EDTA, 0.5% NP-40, 150 mM NaCl (NTEN buffer) containing Complete 
Protease Inhibitor Cocktail and subsequently incubated on ice for 15 min.  The samples 
were then centrifuged for 15 min at 14,000 rpm and the supernatant was transferred to a 
new tube.  Lysates were then pre-cleared with mouse IgG-Agarose beads for 1 hr using a 
rotator.  Immunoprecipitation (IP) was performed overnight on a rotator with either 
mouse IgG-Agarose (IgG IP control) or anti-FLAG M2 affinity gel (FLAG IP).  The next 
day, the beads were washed 3 times with NTEN buffer and protein eluted from beads 
with 1X NuPAGE lithium dodecyl sulfate (LDS) sample buffer at 95oC for 5 min.  The 
samples were then loaded on a Criterion 4 to 20% gradient gel and transferred to a 
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Hybond P membrane.  Immunoblotting was performed with a mouse anti-BRCA2, rabbit 
anti-RAD51, mouse anti-Flag M2, rabbit anti-PALB2 and secondary goat anti-mouse IgG 
HRP conjugate (or donkey anti-rabbit IgG HRP. 
 
Immunofluorescence 
Cells were plated in 4-chamber slides at 100,000 to 200,000 cells per chamber.  The day 
after plating, irradiated samples were exposed to 10 Gy of ionizing radiation (IR).  After 
6 hr of recovery, the cells were fixed in 4% paraformaldehyde/PBS for 15 min and 
permeabilized with 0.2% Triton X-100/PBS for 15 min.  Fixed cells were blocked in 7% 
bovine serum albumin (BSA)/PBS for 60 min.  The primary antibody was diluted in 0.5% 
BSA/PBS and incubated overnight at 4oC.  The primary antibody was rabbit anti-RAD51 
and the secondary antibody was an Alexa Fluor 555 anti goat and rabbit antibody.   DNA 
repair foci quantification was performed using ImageJ. 
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RESULTS 
Generation of an inducible-conditionally-null PALB2 knockout cell line 
We used rAAV-mediated gene targeting to generate a PALB2 knockout in the HCT116 
cell line as described (Figure 1)(152,153,181).  A conditional knockout cell line approach 
was used because of two informative precedents: first, the direct disruption of PALB2 in 
the mouse resulted in embryonic lethal (224).  Second, the FA patients reported to date 
with PALB2 biallelic mutations are not null, but express truncated proteins with potential 
hypomorphic function (197).  Together, these two pieces of data suggested that the 
complete absence of PALB2 expression might not be compatible with viability.  To begin 
to experimentally address this hypothesis, an adenovirus expressing Cre recombinase 
(AdCre) was introduced into the PALB2flox/NEO cell line in an attempt to remove the NEO 
selection cassette and the floxed conditional allele.  However, while 9 of 40 clones 
demonstrated removal of the NEO selection cassette, all of the subclones retained the 
floxed allele (data not shown).  Moreover, when two of the PALB2flox/- cell lines were 
treated with AdCre and 96 clones were screened, all of the viable subclones still retained 
the floxed allele (data not shown).  These two preliminary experiments circumstantially 
confirmed that the isolation of a human cell line lacking the expression of PALB2 was 
likely not biologically possible.  This prompted us to introduce the CreER system into the 
cell line as an inducible way to force the removal of the floxed allele (227).  With the 
addition of tamoxifen or 4-OHT, the CreER translocates to the nucleus and can facilitate 
recombination of the floxed PALB2 allele.  Indeed, the PALB2flox/-:CreER cells effectively 
removed the floxed allele following the addition of 4-OHT to the cell culture media, and 
PCR did not detect any residual floxed allele 24 hr after CreER induction (Figure 1B, 
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lanes 4-7).  The loss of PALB2 protein expression with the addition of tamoxifen further 
confirmed the functionality of the CreER system and establishment of the PALB2-/- 
genotype (Figure 1C).  While the PALB2flox/-:CreER cells have reduced PALB2 expression 
compared to WT (Figure 1C, lanes 1 and 2), the induced PALB2-/- cells had no detectable 
PALB2 protein expression (Figure 1C, lanes 3 to 6). 
PALB2 is essential for cell viability and genomic stability 
To document the effect of the lack of PALB2 expression on cell proliferation, a growth 
curve of the PALB2flox/-:CreER cells compared to WT cells with and without tamoxifen 
treatment was performed (Supplementary Figure S1).  Untreated PALB2flox/-:CreER cells 
had a growth defect compared to WT, suggesting that PALB2 is haploinsufficient.  Even 
more striking, when tamoxifen was added to the cultures the cells no longer expanded but 
instead began to die.  These observations unequivocally demonstrated that PALB2 is 
essential for cell viability and explained why no PALB2-/- subclones could ever be 
obtained from single cells.  PALB2’s tight association with BRCA1 and BRCA2 and its 
involvement in HDR led us to investigate the genomic stability of PALB2-null cells.  
Thus, metaphase spreads were derived from either PALB2flox/-:CreER or PALB2-/- +WT 
cDNA cells 24, 48, and 72 hr after tamoxifen treatment or from cells that were untreated.  
The resulting karyotypes demonstrated that within 24 hr of inducing the PALB2-/- 
genotype with tamoxifen, that highly characteristic FA radial chromosome formations 
could already be observed along with an increased frequency of breaks and fragmented 
chromosomes (Figure 2).  Strikingly, by 48 hr after tamoxifen addition, massive 
chromosomal catastrophe had occurred in 75% of the metaphase cells and an additional 
10% of the metaphase spreads were simply too fragmented to quantitate (Figure 2 and 
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Supplementary Table S1).  Not surprisingly, a low mitotic index was noted for the 
PALB2flox/-:CreER cells at 48 and 72 hr after tamoxifen treatment (data not shown). 
This type of chromosome shattering can be caused by aberrant DNA replication 
(230,231).  To examine if the severe genomic instability in the absence of PALB2 was 
replication dependent, the cells were grown in complete media and in low serum (1% 
FBS) media.  The low serum conditions reduced cell proliferation by 56% and when 
tamoxifen was added, low serum conditions also reduced the cell death resulting from the 
loss of PALB2 by 47% (Supplementary Figure S1).  Therefore, the reduction in cell 
growth and replication was proportional to the reduction in cell death, suggesting that the 
genomic instability observed in the absence of PALB2 was replication dependent.  Taken 
together, these results support the hypothesis that PALB2 is essential for preventing 
replication-dependent genomic instability. 
 
Complementation with PALB2 patient mutations rescues cell viability 
Few FA patients of the FA-N subtype have been reported and these patients typically 
have a severe form of FA associated with an early onset of cancer (138,197).  
Interestingly, even though the patient sample size is small, most of these FA-N patients 
have PALB2 frameshift and/or nonsense mutations that truncate or destabilize the C-
terminus of the protein.  Thus, after establishing that PALB2 function was essential for 
cell viability and genome stability, we set out to understand how these potentially 
hypomorphic patient mutations functioned in the cell.  Three of the FA-N known 
pathogenic PABL2 mutation were selected for analysis: c.1653T>A, p.Tyr551* (Y551X); 
c.2257C>T, p.Arg753* (R753X); and c.3549C>G, p.Tyr1183* (Y1183X) (Figure 3A).  
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Mutations Y551X and R753X are both truncations that eliminate the PALB2 WD40 
domain, which is the binding site for BRCA2, RAD51 and RAD51C.  Y1183X is a 
PALB2 truncation of just the last 4 amino acids of the protein, but has been reported to 
destabilize the 7-bladed β-propeller protein structure formed by the WD40 domain (128). 
In addition to the 3 naturally-occurring PALB2 mutations described above, a recent 
study using next generation sequencing performed on breast cancer patients identified 
several breast cancer patients with VUS mutations resulting from SNPs in PABL2.  This 
study identified 13/2158 (0.6%) breast cancer patients with known pathogenic PALB2 
mutations, but another 56/2158 (2.6%) that had PALB2 VUS mutations (139).  Three of 
the VUSs that resulted in single amino acid substitutions were selected for analysis: 
c.298C>T, p.Leu100Phe (L100F); c.656A>G, p.Asp219Gly (D219G); and c.1699C>T, 
p.His567Tyr (H567Y) (Figure 3A).  Two of the VUS mutations, L100F and D219G, 
were each found in 3 patients from this study, indicating a potentially higher population 
occurrence or pathogenicity.  In addition, two of the VUS mutations, D219G and H567Y, 
were associated with high-risk based on family history.  High-risk was defined as a 
family history of breast cancer before the age of 50 or ovarian cancer at any age or with 
corresponding mutations in a first- or second-degree relative (139).  When these 
mutations were evaluated by the MutationTaster2 web-based software to classify the 
pathogenicity of these SNPs, all three were predicted to just be polymorphisms (i.e., non-
pathogenic) (232). 
Both the FA authentic, PALB2-truncating mutations as well as the breast cancer SNP 
mutations were engineered into a WT PALB2 cDNA and the respective mutant cDNAs 
were then used to complement the PALB2flox/-:CreER cells.  Tamoxifen was subsequently 
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used to remove the floxed PALB2 allele and PALB2-/- complemented cell lines with the 6 
different patient mutation (and a WT cDNA) were successfully obtained, confirming that 
all of the mutant cDNAs were capable of rescuing cellular viability.  Of note, however, 
the Y551X and R753X PALB2 truncating mutations did not complement easily, and 
multiple rounds of tamoxifen treatment were required before complemented cells with 
the loss of the conditional allele could be isolated.  A priori and quite importantly, the 
successful PALB2-/- complementation with Y551X and R753X PALB2 cDNAs (which 
both truncate the C-terminal WD40 domain) strongly and surprisingly implied that the 
BRCA2, RAD51, and RAD51C binding domains were not essential for viability.   
Therefore, it was hypothesized that the N-terminal coiled-coil domain containing the 
BRCA1 binding and PABL2 homodimerization activities was perhaps the essential 
portion of PALB2 that was required for cellular viability.  To test this hypothesis, we 
constructed an additional mutant PALB2 cDNA lacking the coiled-coil domain (ΔCC).  
Surprisingly, complementation was also successful with this cDNA, although 
establishing the cell line also required several rounds of tamoxifen treatment to obtain the 
relevant clones.  In all instances, complementation of viability was confirmed by loss of 
the chromosomal conditional (floxed) allele (Figure 3B, lanes 4-11). 
 
CRISPR/Cas9-mediated targeting to generate a PALB2 mutant cell line 
As further confirmation that viable, hypomorphic mutations can be generated in PALB2, 
a CRISPR/Cas9-mediated gene editing strategy was used to create another PALB2 
mutant cell line.  A guide RNA was designed close to the R753X mutation site in exon 5 
(Supplementary Figure S2)(157).  The CRISPR/Cas9-containing plasmid was transfected 
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along with a ssODN as a donor template for the knock-in of the R753X mutation and a 
novel restriction enzyme recognition site for BseYI.  Screening was performed of the 
edited cells by PCR amplification of the target site, BseYI restriction enzyme digestion 
and subsequently by confirmatory DNA sequencing.  One of the resulting clones (#17) 
had biallelic mutations of PALB2 in exon 5.  One allele of clone 17 contained a one base 
pair insertion resulting in a frameshift and premature truncation in exon 5 (very similar, 
but not identical to R753X).  The other allele had an in-frame, 21 amino acid deletion 
flanked by missense mutations, p.C757W_S778Gdel.  Theoretical expression of the 
second allele should produce a protein containing intact N- and C-terminal domains.  
This biallelic PALB2 mutant cell line is hereafter referred to as the PALB2* cell line and 
was also characterized in the experiments described below. 
 
PALB2 VUS mutations D219G and H567Y are potentially pathogenic  
To confirm the utility of the FA mutant cell lines and to assess the breast cancer VUS for 
pathogenicity, all of the complemented and genetically engineered PALB2 cell lines were 
tested with three different drugs that will induce different types of cellular stress.  The 
hallmark of FA cells is a sensitivity to interstrand DNA crosslinks, such as those 
introduce by the chemotherapeutic MMC.  Therefore, all the complemented cell lines 
were first tested for MMC sensitivity in a colony forming assay.  The cells were plated at 
low density according to their plating efficiency and colony formation was evaluated in 
MMC-treated cells at increasing concentrations (1, 2, and 5 nM) compared to untreated 
cells.  The WT complemented PABL2-/- cells were as equally resistant to MMC as WT 
cells demonstrating that a WT cDNA can completely rescue this phenotype (Figure 4A).  
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In contrast, all but one of the derived mutations demonstrated significant sensitivity to 
MMC at all three concentrations.  The one exception was the breast cancer associated 
VUS, L100F, which was not significantly sensitive to MMC at 1 nM, but was sensitive at 
the two higher concentrations (2 and 5 nM MMC) as compared to WT HCT116 cells 
(Figure 4A).  Thus, all of the mutant cDNAs, some more so than others, were incapable 
of restoring a MMC-resistant phenotype to PABL2-/- cells. 
Replication stress is a known contributor to genomic instability due to the resulting 
DSBs caused by the collapse of stalled replication forks.  Therefore, the ability of the 
PALB2 mutant cell lines to handle replication stress was evaluated by using colony 
forming assays with increasing concentrations (25, 50 and 75 nM) of APH exposure.  
Again, the WT-complemented PALB2-/- cells were as equally resistant to APH as WT 
cells demonstrating the possibility of full complementation (Figure 4B).  All of the 
PALB2 mutant cell lines except L100F were sensitive to the highest dose (75 nM) of 
APH.  However, only H567Y and ΔCC were significantly sensitive to all 3 
concentrations of APH (Figure 4B). 
Lastly, BRCA1 and BRCA2 cancer cells have a demonstrated synthetic lethality with 
PARP1 inhibitors such as olaparib.  Olaparib inhibits PARP1 activity, which is involved 
in single-strand DNA break repair as well as alternative non-homologous end joining 
(233).  To test the sensitivity of the PALB2 mutations, the mutant cell lines were 
evaluated by a colony forming assay with increasing concentrations (50, 100, and 250 
nM) of olaparib compared to untreated cells.  As before, the WT-complemented PALB2-/- 
cells were equally resistant to olaparib as WT cells.  Likewise, similar to the MMC 
sensitivity experiments, all of the mutant-complemented cell lines, except L100F, were 
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significantly sensitive to olaparib at all three concentrations tested.  Interestingly, the 
PALB2* cell line had some resistance to olaparib and was only significantly sensitive at 
the highest concentration (250 nM) tested (Figure 4C). 
Taken together, these data indicate that the PALB2 WD40 domain (with the 
BRCA2/RAD51/RAD51C binding activities) and the coiled-coil domain (with the 
BRCA1 binding and PALB2 homodimerization activities) are essential for MMC, APH 
and olaparib resistance.  In contrast, the breast cancer VUS, L100F, had only mild MMC 
sensitivity and no increased sensitivity to APH or olaparib suggesting that it was (or 
nearly so) as functional as a WT cDNA.  Strikingly, however, and of significant clinical 
significance, the other two breast cancer VUS mutations, D219G and H567Y, both 
demonstrated drug sensitivities comparable to the bona fide FA pathogenic mutations.  
These VUSs do not disrupt any known PALB2 domain, but are apparently highly 
debilitating.  Of additional interest, the PALB2* mutant had only intermediate phenotypes 
for MMC and especially for olaparib sensitivity, indicating that it maintains significant 
PABL2 function, most likely because this allele contains intact N- and C-terminal 
domains. 
All PALB2 mutants are defective in HDR and a full-length PALB2 is essential for 
HDR 
PALB2 has been implicated as the molecular scaffold for HDR repair proteins and a 
coordinator of HDR repair.  Thus, a recombination assay was used to determine the 
ability of the mutant cell lines to carry out HDR (159).  Briefly, 3 plasmids: a DR-GFP 
reporter plasmid, an I-SceI expression plasmid, and a mCherry expression plasmid as a 
transfection control were transfected into the relevant cell lines.  The DR-GFP plasmid 
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contains two non-functional GFP cassettes, one has been inactivated by the inclusion of 
an integrated I-SceI enzyme recognition site along with stop codons and the other is 
inactivated because it is truncated on both the 5’ and 3’ ends.  The I-SceI enzyme can 
thus be used to create a DSB in the first GFP cassette and if HDR is used with the 
truncated GFP cassette, then GFP expression can be restored and HDR positive cells can 
be quantitated by FACS analysis.  The percent repair is determined by the number of 
mCherry and GFP doubly-positive cells within the total mCherry-positive cell population 
(Figure 5A).  Importantly, all of the PALB2 mutants were found to have a significantly 
reduced HDR repair compared to the WT complemented cell line (Figure 5A).  With that 
said, all three of the VUS mutations and Y1183X had a significantly higher percentage of 
HR compared to the FA patient mutations Y551X and R753X, and the ΔCC and PABL2* 
mutants.  A parsimonious interpretation of these results is that rather than a functional N- 
or C-terminus being required for HDR what may be more important is the expression of a 
full length (or mostly intact, as Y1183X lacks just the last 4 amino acids) PALB2 protein 
— a view that is consistent with a putative scaffolding role. 
A RAD51 stabilizing small molecule, RS-1, is known to help stabilize RAD51 
filament formation (183).  To evaluate if RS-1 could improve the HDR rates of the 
PALB2 mutant cell lines, 7.5 nM RS-1 was next included while performing the HDR 
assay.  RS-1 improved the percentage of HDR repair in the WT-complemented PALB2-/- 
cells by 30%, whereas all PALB2 mutants except Y1183X showed little to no 
improvement in HDR efficiency.  RS-1 increased the Y1183X mutant HDR efficiency by 
28%, which was not significantly different from the improvement observed in WT-
complemented cells.  These results indicate that PABL2 is playing an important role in 
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RAD51 filament formation and/or that strand invasion cannot be compensated for by 
RAD51 filament stabilization.  It also implies that the Y1183X mutant is somewhat 
uniquely defective in stabilizing RAD51 filaments and that RS-1 can improve HDR 
specifically for this PALB2 mutant. 
 
Pathogenic PABL2 mutants can complex with BRCA2 and RAD51 
Most of the confirmed FA-N group mutations in PALB2 are nonsense or frameshift 
mutations resulting in premature truncation of the protein’s C-terminus and consequently 
encode proteins that do not bind BRCA2 and have reduced binding to RAD51 (131,196).  
To evaluate whether the PALB2 mutations studied here could still bind BRCA2 and 
RAD51, a co-immunoprecipitation was performed (Figure 6).  Detectable amounts of 
FLAG-tagged PALB2 were successfully pulled down using FLAG antibody beads for 
immunoprecipitation in all of the complemented cell lines except R753X and ΔCC, 
indicating these two proteins may be more unstable than the other mutants (Figure 6, 
lanes 7, 9, 12).  With that said, it is important to remember that these two mutant cell 
lines, while not expressing detectable immunoprecipitable PALB2 protein, are 
nonetheless viable, indicating that some protein must perforce be expressed.  In addition, 
BRCA2 was pulled down in WT-complemented cells (Figure 6, lane 2) and in all the 
VUS mutants (L100F, D219G, H567Y) (Figure 6, lanes 3 to 5) and even in the FA 
mutation Y1183X (Figure 6, lane 8).  As expected, the PALB2 mutant cell lines 
expressing the Y551X, R753X truncations of the WD-40 domain did not bind BRCA2 
(Figure 6, lanes 6, 7, 11).  Interestingly, the ΔCC mutant did not co-immunoprecipitate 
BRCA2 either (Figure 6, lanes 9 and 12), but that could be due to insufficient quantities 
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of stable PALB2 mutant protein.  Intriguingly, RAD51 was pulled down in all of the cell 
lines (Figure 6, lanes 2 to12).  WT HCT116 cells not expressing a FLAG-tagged PALB2 
were used a negative control and, as expected, no detectable BRCA2, PALB2, or RAD51 
protein was pulled down (Figure 6, lane 1).  Since there are two binding domains for 
RAD51, one in the N-terminus and one in the C-terminus of PALB2 that could explain 
how the truncating mutations are still binding RAD51 (Figure 3).  The RAD51 pull down 
also supports the contention that some PALB2 protein is expressed for the R753X and 
ΔCC mutants even if it is below the antibody detection level. 
PABL2 facilitates RAD51 function and PALB2 truncation mutants of the WD40 
domain generally disrupt the formation of RAD51 foci following exposure of cells to 
DNA damage (118,197).  Therefore, since all the PALB2 mutants bound RAD51 as 
defined by co-immunoprecipitation, immunofluoresence was used to investigate if the 
PALB2 mutant cell lines could still form RAD51 foci after 10 Gy of IR exposure (Figure 
7).  As reported, the two PALB2 mutants that truncate the WD40 domain (Y551X and 
R753X) were unable to form RAD51 foci, nor was the ΔCC mutant.  The three VUS 
mutants (L100F, D219G and H567Y) appear to have fewer RAD51 foci than the WT-
complemented cells.  Most interesting was the ability of the Y1183X and PALB2* to 
form RAD51 foci.  This demonstration was especially interesting in light of the previous 
demonstration (Figure 5A) that both of these mutants are defective in HDR.  Taken 
together these results strikingly suggest that BRCA2 and RAD51 binding are not 
sufficient for the normal function of PALB2 in facilitating RAD51 localization, filament 
formation or HDR. 
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DISCUSSION 
The importance of DSB repair and resolution of stalled replication forks in preventing 
cancer, particularly breast cancer, is reinforced by the fact that many genes involved in 
HDR are cancer predisposition genes.  In this study, we created a tamoxifen-inducible 
knockout of PALB2, and demonstrated that it is essential for genomic stability and 
viability.  Indeed, the loss of PALB2 resulted in a rapid and catastrophic genomic 
instability (Figure 2).   We then demonstrated that PALB2 FA-associated mutations are 
hypomorphic and can rescue cellular viability and yet they are still defective in DNA 
repair and sensitive to ICLs and replication stress.  These latter observations are 
important because they define a novel separation-of-function that was previously 
unappreciated in terms of PALB2’s role(s) in cellular viability and DNA repair.  We have 
also characterized the function of three PALB2 VUSs that were discovered in breast 
cancer patients.  While most PALB2 pathogenic mutations identified so far are 
truncations, our results indicate that even single amino acid changes — even ones not 
located in critical structural domains in PALB2 — can significantly alter the ability of the 
protein to enable DNA repair and the response to replication stress. 
 
FA pathogenic mutations 
The three FA-associated mutations, Y551X, R753X and Y1183X, all demonstrated 
significant sensitivity to ICLs, replication stress and PARP1 inhibition, and all were 
defective in HDR, as expected.  However, the Y1183X mutation did have some residual 
drug resistance and HDR function that was not observed with the other two, larger 
truncating mutations.  In addition, the Y1183X mutation was the only PALB2 mutant 
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with increased HR efficiency when the RAD51 stabilizer, RS-1, was used, and the only 
FA truncating mutant that was capable of binding BRCA2 and forming RAD51 foci.  
One possible explanation for these results is that the loss of the C-terminal four amino 
acids does not destabilize the protein as much as had been predicted (128).  Alternatively, 
it is also possible that the instability predicted to be imparted by this mutation does in fact 
occur but that it is overcome by overexpression in our system (e.g., Figure 6), allowing 
for some protein folding and binding of BRCA2.  Regardless, what is perhaps 
mechanistically most important is that this binding of BRCA2, and the recruitment of 
RAD51 to DNA damage foci improved HDR over the full WD40 truncation mutants, 
Y551X and R753X (Figure 6), and (modestly) improved drug resistance (Figure 4).  
Purified PALB2 binds preferentially to ssDNA and D-loop structures and facilitates 
RAD51 filament formation and strand invasion (118,234).  Therefore, the observed result 
that RS-1 improved HR efficiency for Y1183X leads to the conclusion that this mutant 
may be predominately defective in RAD51 filament formation or strand invasion.  
Therefore, the PALB2-mediated binding of BRCA2 and recruitment of RAD51 to DNA 
damage foci is not only insufficient for full HDR activity but it may also not be predictive 
of the pathogenicity for a PALB2 mutation. 
The PALB2* and ΔCC mutants 
The PALB2* and ΔCC mutants provided some additional insight into PALB2 function.  
Since many of FA-associated mutations truncated the BRCA2 binding domain, but 
retained the BRCA 1 binding domain, we had hypothesized that the BRCA1 binding 
domain was the PALB2 feature that was essential for viability.  In addition, BRCA1 has 
been implicated as functioning upstream of PALB2, and that it is required for MMC 
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resistance, HDR and RAD51 foci formation (131,132,134,235).  Therefore, it was 
surprising that the ΔCC mutant, which completely lacks the BRCA1 binding domain, 
rescued the viability of the PALB2-/- cell line.  These experiments surprisingly 
demonstrated that the coiled-coil is not required for viability.  This conclusion must be 
tempered somewhat since there no detectable protein expression for the ΔCC mutant.  
However, the fact that the viability of the PALB2-/- cell line could be complemented by 
this mutation argues strongly that there must be some protein functioning in the cells.  
The observation of RAD51 binding in the ΔCC mutant also argue for some functioning 
residual protein.  As expected, the ΔCC mutant demonstrated severe sensitivity to ICLs, 
replication stress and olaparib, and was defective in HDR indicating that the coiled-coil 
domain (and BRCA1 binding and homo-dimerization domain) were essential for these 
functions.  It is unclear whether the undetectable binding of BRCA2 to PALB2 ΔCC was 
due to the ΔCC domain being essential for BRCA2 binding or, as we believe the more 
likely scenario if it was due to low PALB2 mutant protein levels making detection 
difficult (Figure 6, lanes 9 and 12). 
The PALB2* mutant was also illustrative.  One allele of PALB2* contains a 
mutation that results in a frame shift and truncation (p.760fs*11) comparable in location 
(seven amino acids C-terminal) to the R753X mutant.  However, this mutant performed 
better than R753X in all the drug sensitivity assays, indicating that the other allele, an in-
frame deletion of 21 amino acids with an intact WD40 domain (p.C757W_S778Gdel) 
was likely functioning to some extent.  With that said, the putative intact WD40 domain 
and the demonstrable RAD51 foci formation did not correlate with efficient HDR.  In 
addition, RS-1 did not improve HDR in the PALB2* mutant.  Indicating possible defects 
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with D-loop stabilization or DNA binding considering the deletion occurs near the 
MRG15 binding site and may affect chromatin association.  Interestingly, internal protein 
deletions of PALB2 have been found before to rescue functionality of the protein before.  
A revertant clone from Y551X was found that deletes exon 4 completely and provides 
rescue of MMC sensitivity and RAD51 foci formation.  Also, a hypomorphic PALB2 
mutation associated with a patient with a more mild form of FA-N had C-terminal 
truncation mutation (c.1676_1677dleAAinsG; p.Gln559ArgfsTer2) and second mutation 
that results in an in-frame skipping of exon 6 (c.3586+1G>A;p.Thr839_Lys862del).  The 
cells from the FA-N patient can bind BRCA2 and form RAD51 foci.  Therefore, it 
interesting that PALB2* mutant with an in-frame 21 amino acid deletion in exon 5 is still 
sensitive to ICL, APH and olaparib.  However, PALB2* has some partial resistance to 
olaparib compared to the other pathogenic mutations (PALB* is only significantly 
sensitive at the highest concentration of Olaparib) which is similar to a report by 
Bleuyard et al., that reported MMC sensitivity but not olaparib sensitivity when ChAM 
motif was deleted (214).  In summary, central deletions of PALB2 can recover some 
functionality of the protein in experimental assays, and could result in less severe clinical 
phenotypes. 
Breast cancer SNPs 
The three breast cancer associated PALB2 SNPs from this study were selected based on 
association with high family history or repeated occurrence in the breast cancer patients 
tested in the study by Tung et. al.(139).  The SNPs were all classified as variants of 
unknown significance (VUS) and had not been previously reported.  All three of the 
SNPs produced full length PALB2 protein that was well expressed (Figure 6).  However, 
123	  
	  
the defective phenotype for the D219G and H567Y mutants observed in the drug 
sensitivity assays (MMC, APH and olaparib, Figure 4) was surprising and comparable to 
the sensitivity of the highly pathogenic WD40 truncating mutations.  Further analysis 
revealed that all three of the mutants were defective in HR, and the HR efficiency could 
not be improved with RS-1.  In addition, all the SNPs were capable of binding BRCA2 
and forming RAD51 foci (Figures 6-7).  However, as seen with the Y1183X, even 
pathogenic mutations can bind BRCA2 and form RAD51 foci.  Therefore, the 
experimental data along with a strong family history for breast/ovarian cancer for the 
D219G and H567Y mutations supports the conclusion that they are potentially 
pathogenic.  In conclusion, we have developed a cellular model system that is being used 
successfully to evaluate PALB2 cellular functions and screen variants for pathogenicity. 
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FIGURE LEGENDS 
Figure 1.  Generation of the inducible-conditional PALB2 knockout (A) rAAV 
targeting scheme for PALB2.  The first round of targetin used a conditional rAVV vector 
to knock-in a NEO selection cassette (green rectangle) and flank PALB2 exons 2 and 3 
with lox P sites (yellow triangles).  AdCre was used to remove the NEO selection cassette 
creating the PALB2flox/+ cell line.  The second round of targeting used a knock-out rAAV 
vector to knock-out PALB2 exons 2 and 3 and replace them with a NEO selection 
cassette.  AdCre was used again to remove the NEO selection cassette and to remove the 
floxed exons 2 and 3 on the conditional allele.  However, only clones that retained the 
floxed exon were recovered after subcloning creating the PALB2flox/- cell line.  Therefore, 
an inducible Cre recombinase system, CreER, was introduced to the cells to force the 
removal of the conditional allele with the addition of tamoxifen (4-OHT), creating the 
PALB2flox/-:CreER cell line.  The addition of tamoxifen to the culture media results in 
forced removal of the conditional allele and creation of the PALB2-/- cell line. (B)  
Schematic of the different alleles and sizes that can be detected with the primers used in 
the PCR.  The untreated PCR panel shows the WT HCT116 parental cells with a single 
band across exons 2 and 3 (Lanes 2-3) while the two independent clones of PALB2flox/-
:CreER cells (3 and 31) amplify two alleles, the flox and null bands (Lanes 4-7).  The 
tamoxifen treated panel (+4-OHT) shows that tamoxifen does nothing to WT cells (Lanes 
2-3), but within 24 hours of adding 10 nM tamoxifen to the PALB2flox/-:CreER cells, the 
floxed allele is no longer detectable and only the null alleles are amplified, confirming 
the inducible PALB2-/- cell line (Lanes 4-7). Negative control (Lane 8).  1Kb Plus DNA 
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Ladder (Invitrogen) (Lanes 1 and 9) (C)  Western blot analysis demonstrating reduced 
PALB2 expression in the PALB2flox/-:CreER cells and loss of PALB2 after the addition of 
tamoxifen.  80 ug of whole cell lysates from WT HCT116 cell (Lane1), and PALB2flox/-
:CreER clone 3 (Lanes 2-6), untreated (0) and 24, 48, 72 and 96 hours after the addition of 
tamoxifen.  Ku86 was used a loading control. 
Figure 2.  PALB2 is essential for genomic stability (A) Example metaphase spreads 
from cytogenetic analysis of PALB2flox/-:CreER cells untreated, 24 and 48 hours after 10 
nM tamoxifen added to the cells to induce the loss of PALB2.  The untreated cells 
demonstrate the PALB2flox/-:CreER cells have a stable and diploid karyotype of the HCT116 
parental cell line.  24 hours after 4-OHT added to the media, radial chromosomes (red 
arrows) that are characteristic of FA patient cells can be found.  48 hours after 4-OHT is 
added, chromosomal catastrophe has occurred in 75% of the metaphases analyzed.  
Figure 3.  PALB2 structure and location of patient mutations that rescue cell 
viability (A) PALB2/FANCN cDNA exons and bp (base pairs) and the FANCN protein 
aa (amino acids) are numbered and aligned with the binding and structural domains of the 
protein.  The location of the PABL2 patient mutations selected for analysis are plotted. 
(B) The same PCR primers from Figure 1B were used to confirm that all the PALB2 
mutant cDNAs had complemented viability of the PALB2-/- cell line.  WT HCT116 cell 
have a single band across exons 2 and 3(Lane 2), the PALB2flox/-:CreER cells have the flox 
and null bands (Lane 3), and the complemented clones only have null bands and no 
endogenous PALB2 (Lanes 4-11).  The null bands are different sizes due to the 
conditional and knock-out rAAV vectors being designed with different size deletions of 
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intronic sequence surrounding the targeted exons. No template negative control (Lane 12) 
1Kb Plus DNA Ladder (Invitrogen)  (Lanes 1 and 13) 
Figure 4.  Drug sensitivity assays demonstrate PALB2 VUS mutations D219G and 
H567Y are potentially pathogenic.   Colony formation assays were performed to test 
drug sensitivity for MMC, APH and Olaparib.  Cells were plated at low density in 6-well 
plates according to their plating efficiencies. The next day, media untreated or with drug 
was added to the cells.  The cells were allowed to grow for 12-14 days then fixed, 
stained, and counted.  The percent clonogenic survival was determined from the average 
number of colonies from the untreated wells.  The reported results are the average from a 
minimum of 6 replicates from a minimum of 2 independent experiments.  Error bars 
represent the SEM (standard error of the mean) (A) MMC sensitivity of the PALB2 
mutants was tested in 0, 1, 2, and 5 nM MMC added to the media.  (B) APH sensitivity of 
the PALB2 mutants was tested in 0, 25, 50 and 75 nM APH added to the media.  (C) 
Olaparib sensitivity of the PALB2 mutants was tested in 0, 50, 100 and 250 nM Olaparib.  
P-values are provided in Supplementary Table 3. 
Figure 5.  All PALB2 mutants are defective in HR (A) HR (homologous 
recombination) repair assay was performed on all PALB2 mutant cell lines.  The percent 
repair was normalized to the average repair efficiency determined from the PALB2-/- 
+WT cDNA (WT) complemented cell line.  (B) 7.5 nM RS-1 was added to the media 2 
hours prior to transfection with HR assay plasmids, and replenished 24 hours later.   
Otherwise, the HR assay was performed the same as in (A).  The change in repair 
efficiency was determined by subtracting the normalized repair efficiency with RS-1 
from the normalized untreated repair efficiency and determining the percentage based on 
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the normalized untreated repair efficiency.  Data is averaged from a minimum of 6 
replicates from 2 independent experiments.  Error bars represent the SEM (standard error 
of the mean). P-values are provided in Supplementary Table 3. 
 
Figure 6.  Pathogenic PABL2 mutants can complex with BRCA2 and RAD51  Co-
immunoprecipitation of FLAG-tagged PALB2 immunoblotted with anti-BRCA2, anti-
PALB2 and anti-RAD51 antibodies. (Lane 1) negative control of WT HCT116 cells 
without expression of FLAG-tagged PALB2, and has no BRCA2, PALB2 or RAD51 
binding.  (Lanes 2-5) PALB2 complemented cell lines with WT, L100F, D219G, H567Y 
all express a full length PALB2 protein, and bind BRCA2 and RAD51.  (Lanes 6 and 11) 
Y551X clones 1 and 13 express a truncated protein and is variably expressed between the 
two clones.  Neither Y551X clone binds BRCA2, but both bind RAD51. (Lane 7) R753X 
has no visible PALB2 protein detected and no BRCA2 binding, but RAD51 is pulled 
down (Lane 8) Y1183X has PALB2 expression, BRCA2 and RAD51 binding (Lanes 9 
and 12) ΔCC has no visible PALB2 protein detected and no BRCA2 binding, but RAD51 
is pulled down (Lane 10) MWM (molecular weight marker) 
Figure 7.  WD40 domain is essential for RAD51 foci formation, but RAD51 foci are 
not sufficient for efficient HR  WT HCT116 cell and PALB2-/- complements were 
plated in 4 chamber slides.  Cells were exposed to 10 gy IR and allowed to recover for 6 
hours prior to fixing and staining by immunofluorescence.  50 cells were evaluated per 
cell line for RAD51 foci. 
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Supplementary Figure S1. PALB2 is essential for cellular viability and cell death is 
replication dependent (A)  Growth curve of WT HCT116 cells and PALB2flox/-:CreER 
cells clones 3 and 31 with and without tamoxifen (4-OHT) treatment.  Cells were plated 
in 6 well plates with or without tamoxifen.  Cell counts were collected at day 3, 5, 7 and 
11 after tamoxifen treatment in triplicate.  Error bars represent SD (standard deviation). 
(B) The loss of PALB2 results in replication dependent cell death was confirm by a 
replication assay.  PALB2flox/-:CreER cells were grown in complete media (10% FBS) or in 
low serum media (1% FBS) and either with or without tamoxifen.  Cell counts were 
collected in triplicate on day 2 and day 4 after tamoxifen treatment.  The change in cell 
count between days 2 and 4 was determined and the percent change was determined from 
the average cell count on day 2.  Results from two, independent PALB2flox/-:CreER clones 
were averaged.  Error bars represent SEM (Standard error of the mean).  Low serum 
conditions reduced cell proliferation by 56% and when tamoxifen was added, the low 
serum conditions also reduced the cell death resulting from the loss of PALB2 by 47%.  
The reduction in cell growth was proportional to the reduction in cell death, confirming 
that cell death was replication dependent. 
 
Supplementary Figure S2.  CRISPR/Cas9 targeting of PALB2 exon 5 demonstrates 
biallelic mutations are hypomorphic and rescue viability 
A) Schematic of the CRISPR/Cas9-mediated gene targeting to knockout PALB2  in WT 
cells to create biallelic mutations. A guide RNA was designed targeting PALB2 exon 5 
with the Cas9 cut site in proximity to the R753X mutation (c.2257C>T;p.Arg753*).  A 
ssODN (single stranded DNA oligo) donor was provided for knock-in of the R753X 
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mutation, a novel restriction site of BpuEI, and a codon optimized mutation of the PAM 
sequence.  After transfection with Cas9, guide RNA, and ssODN transfected cells were 
FACS sorted for transient Cas9-GFP positive cells and subcloned.  Subclones were 
screened for targeting by PCR amplification of the targeted region and subsequent BpuEI 
digestion.  WT sequence will cut once with BpuEI resulting in two bands (342 and 172 
bp) a heterozygous knock-in would have 4 bands (342, 250, 172, and 92- not visible).  No 
clones with possible homozygous knock-in were found.  Alleles were sequenced from 
clones with potential heterozygous knock-in.  Sequence confirmation of alleles revealed a 
heterozygous KI of R753X in clone 83 and biallelic hypomorphic mutations in clone 17. 
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Data generated in Figure 7 by Avani Gosalia and Elizabeth Thompson 
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DISCUSSION 
 
Fanconi anemia is a challenging disease to treat due to the heterogeneity in severity and 
symptoms of the individual patients.  In addition, the DNA repair defect in FA is a double 
edge sword, resulting in cancer predisposition, but also making them intolerant to the 
typical cancer treatments of chemotherapy and radiation.  Through my PhD work, I have 
created five isogenic knockout cell lines in FA proteins representing the 3 different 
groups of the FA pathway in order to study the different cellular phenotypes.   My overall 
goal was to gain mechanistic insight at the cellular level that could lead to a better 
understanding of the disease heterogeneity and potentially improved treatment options for 
FA. 
 
FANCD2 and FANCI in the replication stress response 
The monoubiquitination of FANCD2 is a key functional step in the FA pathway in ICL 
repair, and is dependent on the presence of FANCI(145,166).  In addition, FANCD2 and 
FANCI co-localize together at the sites of DNA damage (145,166).  Therefore, the 
concept of FANCD2 and FANCI having separate function from the ID2 complex and 
without monoubiquitination was, and still is paradigm changing.   Some of the initial 
evidence for this came from the Sobeck laboratory utilizing Xenopus extracts revealing 
that FANCD2 had functions independent of FANCI in stalled replication fork restart and 
in interaction with BLM, a HJ resolvase (69,151).  Therefore, we created the FANCD2, 
FANCI, and FANCI/FANCD2 double knockout isogenic cell lines for the investigation 
of FANCD2 and FANCI in the replication stress response to further clarify any 
separation of function.   
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Important to establishing these null cell lines as cellular models for FA disease, we 
needed to establish they were consistent with FA patient cell lines and previous studies.  
Consistent with previous reports, we found that FANCD2 and FANCI were co-dependent 
for monoubiquitination and ICL repair, and partially dependent for protein stability, 
nuclear import and chromatin localization (87,145,236).  We confirmed previous work in 
the Sobeck laboratory, that non-monoubiquitination FANCD2 could be recruited to 
chromatin and aid in stalled replication fork restart and new origin firing, independently 
of FANCI (69,150).   
 
We made several novel contributions, including the establishment of the isogenic 
FANCD2, FANCI and FANCI/FANCD2 double knockout cell lines, since to our 
knowledge there had been no previous reports of such cell lines.  Our novel findings also 
include that the D2-/-, I-/- and the ID2 double knockout cell lines are viable, therefore 
neither FANCD2 nor FANCI is essential for viability.  However, both FANCI and 
FANCD2 contribute to cell proliferation.  In addition, we found that FANCD2 has a more 
vital role in HDR than FANCI, and FANCD2 is involved in RAD51 filament formation 
and/or stabilization to promote HDR.  Furthermore, we found that FANCD2 deficient 
cells were highly sensitive to low dose replication stress, and surprisingly, FANCI 
deficient and FANCI/FANCD2 double deficient cells were not.  The sensitivity of the 
FANCD2 deficient cells to replication stress was not due to increased DNA damage, 
reduced recruitment of HDR repair factors, or activation of DDT pathway.  Instead, we 
found evidence that FANCD2 may negatively regulate FANCI-mediated cell death 
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following replication stress. Altogether deducing important functional differences 
between FANCI and FANCD2 and how they regulate each other in alternative functions. 
 
PALB2/FANCN is an essential gene and patient mutations are hypomorphic  
PALB2/FANCN is an important tumor suppressor and is associated with both FA and 
breast cancer susceptibility.  It has been implicated as a molecular scaffold for HDR that 
coordinates the function of multiple proteins including BRCA1, BRCA2, and RAD51 
(129,130).  Taking into consideration that FA-N subtype patients with PALB2 mutations 
often have residual or truncated protein expression (197,225), and the attempted mouse 
PALB2 knockout was embryonic lethal (224), led us to hypothesis that PALB2 was an 
essential gene.  Therefore, we generated a novel PALB2 conditional null cell line, and 
incorporated an inducible Cre recombinase systems, CreER.  With the addition of 
tamoxifen, the CreER system induces the removal of the conditional allele, resulting in a 
PALB2 null cell line.  Using this inducible PALB2 null cell line, we confirmed that loss 
of PALB2 results in replication dependent chromosomal catastrophe.  Unequivocally, 
demonstrating that PALB2 is an essential gene for genomic stability.  This conditional 
PALB2 null cell line allowed us to investigate the function of PALB2 mutations through 
complementation with mutated PABL2 cDNAs and subsequent removal of the floxed 
allele with tamoxifen.  Three truncating FA-N subtype (PALB2) patient mutations were 
capable of rescuing cell viability and confirmed that these truncated PALB2 proteins 
were in fact hypomorphic.  Two of the FA-N mutations completely removed the C-
terminal WD40 domain and the other was predicted to destabilize this WD40 motif 
(128,138,197).   Therefore, complementation by these three FA-N patient mutations 
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demonstrated that the C-terminal WD40 domain, which is the BRCA2, RAD51, 
RAD51C, and POLη binding domain(128,196), is not essential for viability.  We then 
hypothesized that it was potentially the N-terminal coiled-coil domain, which is the 
BRCA1 binding and PALB2 homo-oligomerization domain (132,208) that may be 
performing the essential function for viability.  Therefore, we tested if PALB2 with 
deletion of the coiled-coil domain could complement the PALB2 null cell line.  
Surprisingly, this Δ coiled-coil PALB2 mutant was also able to complement viability, 
therefore the N-terminal coiled-coil domain and BRCA1 binding domain is not essential 
for viability either.  Finally, we complemented the PALB2 null cell line with three 
PALB2 SNP mutations identified in breast cancer patients through a next generation 
sequencing study(139). These 3 SNPs all result in single amino acid substitutions with 
unknown pathogenicity, and were classified as variants of unknown significance (VUSs).  
All three of the breast cancer associated SNPs complemented viability of the PALB2 null 
cell line as well.  In conclusion, neither the WD40 nor the coiled-coil domain are 
essential for viability indicating that the ability to form the BRCA1:PALB2:BRCA2 
complex is not the essential function of PALB2 for cellular viability. 
We further characterized the patient mutations and determined that the WD40 and coiled-
coil domain are essential for resistance to ICLs, replication stress and PARP1 inhibition.  
In addition, the WD40 and coiled-coil domains are essential for BRCA2 binding, RAD51 
localization, and efficient HDR.  Interestingly, all three of the breast cancer associated 
SNPs were also defective in HDR, despite the ability to bind BRCA2 and form RAD51 
foci.  Furthermore, two of the breast cancer associated SNPs were equally sensitive to 
ICLs, replication stress and PARP1 inhibition as the truncating and pathogenic FA-N 
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associated mutations.  Thus, indicating that two of the VUSs (D219G and H567Y) are 
potentially pathogenic, which are the same two VUSs that were assessed as high risk 
based on family history (139).   
In summary, the WD40 and coiled-coil domains are required for resistance to ICLs, 
replication stress, and PARP1 inhibition, and for efficient HDR, but not for cellular 
viability.  Furthermore, we have developed a novel cellular system for determining the 
mechanistic function of PALB2, functionally evaluating PABL2 mutations and 
characterizing potential pathogenicity.   
 
FUTURE DIRECTIONS 
 
The generation of these isogenic cell lines from the three different protein groups of the 
FA pathway provide an opportunity to study the pathway in more holistic approach.  All 
of the cell lines are sensitive to ICL inducing agent, MMC, however, these cell lines have 
varied sensitivity to replication stress.  The ability to investigate the different responses of 
the FA cell lines to different cellular stresses could lead to better insight into disease 
heterogeneity and possibly to improved or personalized treatment based on the gene 
mutations.  The following outlined projects have already been started with my collection 
of isogenic FA cell lines. 
 
Fanconi anemia proteins in replication stress 
In chapter 2, we investigated the separation of function for FANCD2 and FANCI proteins 
in replication stress and found that FANCD2 null cells are highly sensitive to low levels 
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of replication stress, but FANCI null cells were not (Chapter 2, Figure 5 A, B).   
Furthermore, when the FANCD2/FANCI DKO was made, it took on the FANCI null 
phenotype of not being sensitive to low level replication stress.  We chased down several 
possible explanations for this observation, such as increased DNA damage, recruitment 
of HDR factors and activation of DNA damage tolerance pathway, however none of these 
were any different in any of the knockout cell lines.  We did find an elevated phopho-p53 
and p21 expression in the FANCD2 deficient cells which seemingly indicates that in the 
absence of FANCD2, FANCI is inducing apoptotic cell death in response to low level 
replication stress.  Also, this would explain why the FANCD2/FANCI DKO took on the 
FANCI null phenotype for survival, because FANCI was not present to induce the 
apoptotic response.  A recent study has also implicated FANCI as a negative regulator of 
AKT, and when FANCI was depleted, resulted in reduced apoptosis (237).   Therefore, I 
am using RNAseq to further clarify the different responses between FANCD2 and 
FANCI deficient cells to replication stress.  WT, D2-/-, I-/- and ID2 DKO cells (two 
independent clones of each cell line) were either untreated or treated for 24 hours with 
100 nM APH.  This treatment and time frame is sufficient for an observable cell cycle 
alteration in response to the APH (data not shown). RNA was isolated and prepared for 
RNAseq analysis.  Sequencing of the samples has just been completed and analysis is 
pending.   We expect this investigation to help clarify the different replication stress 
responses of these cell lines.  
However, in addition to FANCI and FANCD2, there are differences in other FA proteins 
in sensitivity or resistance to low level replication stress.  In Chapter 3 we demonstrate 
that FANCN mutations are also sensitive to APH induced replication stress (Chapter 3, 
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Figure 4B).  In addition, my preliminary data with the FANCA null cell line indicates 
that it is not sensitive to low level APH-induced replication stress (data not shown).  
Inferring that FANCD2 and FANCN may have active roles in the replication stress 
response and FANCI and FANCA may not.  Therefore, FANCA null (two clones) and 
FANCN (PALB2*, Y1183X, and R753X) were treated with and without 100 nM APH 
for 24 hours, and prepared for RNAseq analysis.  Sequencing of the samples has just 
been complete and analysis is pending.   
We are collaborating with Dr. Filip Zelezny at the Czech Technical University in Prague 
for bioinformatic analysis.  We expect that comparison of this RNAseq analysis of the 
different FA pathway proteins (FANCA, FANCI, FANCD2, and FANCN) in replication 
stress response will reveal mechanistic insight into their differing responses and possibly 
lead to potential drug targets to investigate for FA patients. 
 
PALB2 VUS screen 
Next generation sequencing is becoming more common for breast cancer susceptibility 
genes (125,139).  While the discovery of a pathogenic mutation is informative for a 
patient and can help guide preventative or cancer treatments, the diagnosis of a VUS is 
not beneficial.  Therefore, we have been developing a large-scale screen of VUS 
mutation for breast cancer using the PALB2 conditional null cell line to determining the 
function of PALB2 VUS mutations and define potential pathogenicity.   
Creation of PALB2 variant cDNA Library:  We selected over 90 different PALB2 
variants including the following: VUS mutations identified in breast cancer patients(139), 
known pathogenic mutations associated with either breast cancer or FA-N subtype, and 
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general population SNPs.  Next, we used site directed mutagenesis to incorporate the 
mutations into the PALB2 cDNA.  In collaboration with the Chad Myers laboratory at the 
University of Minnesota, we have designed DNA barcoded primers and we are currently 
in the process of barcode labeling each of the individual patient mutation containing 
cDNAs.  After the cDNAs are barcoded, they will be cloned into a FLP-in system 
expression vector to create an expression library of barcoded cDNAs.   
Creating the FLP-In PALB2flox/-;CreER  cell line:   We have also been working to 
incorporate the FLP-In System (Invitrogen), FRT site into the PALB2flox/-;CreER  cell line.  
The FLP-in system works by using the FLP recombinase to site specifically integrate the 
expression vector, containing the PALB2 cDNAs into the genome through a FRT site.  
We are currently using CRISPR/Cas9 to site specifically integrate the FRT site into the 
AAVS1, safe harbor locus, in the PALB2flox/-;CreER  cell line.   
Screening PALB2 mutations:  We will then transfect the barcoded PALB2 cDNA 
expression library along with a Flp recombinase expression plasmid into the FLP-In 
PALB2flox/-;CreER  cell line and select for cDNA integration with hygromycin. 
Subsequently, the conditional PALB2 allele will be removed with tamoxifen, however an 
untreated population (no tamoxifen) will be collected to determine baseline of 
incorporated cDNAs.  The tamoxifen treated transfected population will then be divided 
into 4 treatment populations including the following:  untreated, MMC treatment (ICL 
inducing agent), APH treatment (replication stress), and olaparib treatment (PARP1 
inhibitor).  After treatment, cells from each treatment group and baseline will be PCR 
amplified over the cDNA barcoded region with indexing primers to identify the treatment 
groups and baseline.  These samples will then be sequence for identification of the 
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PALB2 barcoded cDNA.  Proportions of barcoded cDNAs for each variant can be 
compared to the baseline transfected population for each treatment condition to determine 
viability with drug treatment.  Risk stratification can be accomplished by the shear 
number of individual cells that can be screened by sequencing.   
We expect this variant screen to identify and provide evidence of potential pathogenic 
mutations within the VUS population. 
 
PALB2 post-translational modifications for improved gene targeting 
Two recent studies have implicated PALB2 post-translational modification as having a 
strong influence in the efficiency of HDR and its cell cycle control.  In the first study, 
Buisson et al. found that the ATR promotes HR through PALB2 by facilitating a S59-
S64 phosphorylation switch on PALB2 (238).  The phosphorylation of PALB2 S59 by 
ATR promoted the PALB2:BRCA1 interaction and PALB2 localization, and the hypo-
phosphorylation of PALB2 S64, a CDK phosphorylation site, also promoted this 
interaction.   Therefore, the PALB2 S59E/S64A mutant increased HR efficiency over WT 
PALB2.  In the second study, Orthwein et al. found that PALB2 N-terminal lysines (K20, 
K25, and K30) are critical for cell cycle regulation of the BRCA1:PALB2 interaction 
(211).  Ubiquitination of these critical lysines by the E3 ubiquin ligase composed of 
KEAP1 is sufficient for preventing the BRCA1:PALB2 interaction in G1 phase of the 
cell cycle.  They also found that they could increase HDR in G1 cells by deleting the 
KEAP1 binding motif (ETGE) in the PALB2 N-terminus or by mutating the N-terminal 
lysines (K20R, K25R, and K30R).  Therefore, based on these two studies, site directed 
mutagenesis on the PALB2 cDNA was used to create the following mutations:  PALB2 
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S59E/S64A, PALB2 K20R, PALB2 K25R, PALB2 K30R, PALB2 K20/25/30R, PALB2 
ΔETGE.  All of the PALB2 mutations listed were able to complement the PALB2 null 
cell line, and therefore rescued viability.  Further experiments are pending to investigate 
the effect of these mutations on gene targeting frequency and their ability to influence 
gene targeting in G1 cells. 
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